{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment",
      "version": "1.0.1",
      "authors": "Sandra Spalek",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/56d6631d06deeead416b3b5100d3b4b8d88c29c6/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/lombardo2015.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "(-)-cotinine",
      "id": "394090032ca1176f3f7350b00cb521d45b54d4d0a81cc2198fe0b4f9f57d513e6247b0b13e50edbbca738fd27a12ef45f7c8f6435f27e213502b05eff7502ca2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 40",
      "id": "2ca2eb795438fe9e0f24c1e9d332717de5e344ddfee00ce8df89c5b901d85db5994d6ffd383e40a90bde264f33e75b220476b3de86c89f0658bf281c872f0bb6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 42",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "pregnenolone sulfate",
      "id": "c169da5b146e5c4b5e3eb5ae2aa55dc75cdddc4b74093083c6dfec574ac6f28b078bf253d68b54e35c74b4921b22f11f07feb7a34c33c60577384ddba729dc73"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "methyllycaconitine",
      "id": "94234135ae5df04da5266496da70c4f3b3ebab6585057c521ecd6d2b6d8ff7f209d5fb77fba5ca82f4b767e019702f0aa3d4e6230a3ac01f85c0ebeff8879b6b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "neurotransmitter",
      "id": "bece6d10e96b69785dbd4c8bab8cbdcd754ff9a5139cabd93dab71c006f16c4b150a518aa934dc852c07fe26a629610104fdc8695476b406a886a07b935c6ccd"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "simvastatin",
      "id": "ae75f3e4fc31e8a726708aec0f7d3023c153e2e7bb68fa993c0f311672f04fd2450bb7e0c8c5b335887f0452d795f262a80363bbe5b9b2ce07ce015d62935034"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "glutamatergic synapse",
      "id": "3ef3c97b0a1c06387e4481e1c4fdb7aacc58926621b600007c6c912a2b6b045b64ce8fc6700bd17381aa95dcb299f707f36853a156c4b72e43c63af91ab970eb"
    },
    {
      "function": "Abundance",
      "namespace": "GO",
      "name": "synapse",
      "id": "cc12602eef45267795bef1781b57fdcfc0800fd22ea1a8c57746d2be9789ec52c582f9244ba1318f068bf1cfa150d96ad79553596c1e96633df8fa625ad1af74"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "4-OH-GTS-21",
      "id": "abde9f97246a68552d7a97717b63900994bd32dfa2e019174bf7e02b93ad23870eee8f31a8fb560e39be9a825a6871788364a96fbe516336e18400c7fa80d403"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "PTI-125",
      "id": "79300d5d98e058ab5434a5de430d1d712e05974b10dc36f8a91c3b5f46a86bd290326cf03d9cb4582fb1da22d8004cafdebb517a803836d84146325f6d8b6d86"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "S 24795",
      "id": "2eab350579ee91781b3b0c7ad690137b1106f81e581bb540cfac2293a3abdf630854dcda5f75d52b081cd431bc6934e421fcc4e2af6bacfac792bf960bad15f2"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "alpha-4 beta-2 nAChR",
      "id": "a9b7c683882f97e9a781f82541ce483ce9d7ed6adcca7af1876821e91eb3b587dd80ed1ee838df6881ff8e46fbe98c6bd66231f3476dfddc0b944dfd4ba89aa6"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "alpha-7 beta-2 nAChR",
      "id": "f7a331628c0bc7e2a3a89c1a79ce55ea88bdd5a5beb39afc6bd1ad19ee7014029b40bb59bf3b2f31ed9a0ee528927151968133625aec4720669b28b973c56cd8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta 40 oligomers",
      "id": "be66ec72d4d3c7d7d75ee305b26176f00c8a3dd769be9da7dc325d4ae7cee898d888631884b3bcb3115782e15e1f1a936894b851e20e7afab1ec6039a0c68ac7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta 42 oligomers",
      "id": "c4cea9209f4b03860743b8b965984b1e648693cb38a36ab07a752a2b1afeb48dccb0075fd82abcf3a2c0f993557de9ede492028ef3369d6d0589bc0ce9c57951"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta aggregates",
      "id": "1d739f6eba3532950fc068e81f7aea675ce76d42a049b5a301ad8bccf2f503d6c2a79c9d417d4d35cc760c340b5db2513536b3c420156a92bda3605be3537740"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta oligomers",
      "id": "a0fc661406161db12bdd89333a13d0ee89b3aa089d5eb16676962cae3efd25d4d3dd6e593dbcaebf5fc0c26f9c8c070a98f2ff0fb94a0d52412c0fa0bf6c5b3b"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "beta-2-containing nAChR",
      "id": "8f35d745b8594a75cec26426602ac5b8c08996ff27c1e4d41e9076e42fc677a58125713403cb8c017f08a2b9bcf5f707f4177bba19dac41a1ef58a71432989cd"
    },
    {
      "function": "Abundance",
      "namespace": "HP",
      "name": "cholinergic neuron",
      "id": "0c25a7e89773f21e2073ca1b106679162a88eea367761fde403484630091020a366456ee2e121fdf727d55e5fd9fab9e411b47872f9c5339e514f2ae8bbad2de"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cerebral Cortex",
      "id": "d570f84dde08e8887b0ba3cb15f79f0f4378d9c7417d64d2a363380e917313da6df600a00c005cef2a697249feaeb07da95f500476083923a8f77b9caedb6e35"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cysteine Loop Ligand-Gated Ion Channel Receptors",
      "id": "1a15aee5668d70b64eadd0d284c0b98ac81244eddd23204971bf3dd28bb362cfe0821547529825cfe670491baac229d063cc769b302f306757fe827061a6bc9b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Cholinergic",
      "id": "d3bf8fdebccce142752b9fc8505dbbf0b20681a2282315d7e14f15ef75281690d8bc75e6b66c170ad6f85c246d4cedb6cdc3b4ba719bd4d622c3a1e2a60d96c8"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Glycine",
      "id": "fafd58a4ec59c732316f7ba77f3ef37d404e4d914c0d4460e39e8397dedf54103096d8397c448d579a30e78e8c353ffcd73a1d3c2863eafdc7220ade9d6af7ad"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, N-Methyl-D-Aspartate",
      "id": "bc0c849274509856f0839b39c84ee4c4d06be886e9c4a160c019e566da4f7b7da0f773b5326d9d72ab53f350fa5ff3371b3cf66ae89e844579e4eb6102565963"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Serotonin, 5-HT3",
      "id": "7591d789fee5b8b9e4e6c6810fbf993ca728f2b0e700c11a1ed3ee9f62e0eaa3cf907b281903ad04c618b2d26599643c263be36e20707fcea879490403faf495"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "White Matter",
      "id": "2955560f6e70748b84bd1dc261fe6a5ff651e69b646fec26ac6cf206ee733b8dc8b27ccd791f9c913426feade19fc741959adb2902094ed7c502363505fbb02e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "alpha7 Nicotinic Acetylcholine Receptor",
      "id": "24bfa0a4dedd705b999b510936aa1c989978fdeec807bf3046bd5178bd8e69ebbf2b1d2d2cd30ce5df8058656f59f497172cea193c9743a405bfb38be1aac50b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Bungarotoxins",
      "id": "e82ea3e9e348ccc642bfadc616f1a99ecd72a491d90148c9f3dab9d287736cbe6dc1c75aa356f12fe0d4f03ed52017ac9fd4193be328c15a06a0c26397db3fd2"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "5311278",
      "id": "ff81d119cda1e470274cf159ad465f21316788516511107a8bb3ff4710f153ea6b47866648d59fba863fec885bb7d4cbaebf7ae31c0c7790cfabaf04c4f3b108"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "637026",
      "id": "fe0649ff4755366984d208a501dce61a63e2b03d06cf6f933774281c20f3d1247968273f77997a396fa4a9b5364d4e6f23f9e28d3365403cd7857298a0637d81"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "9928899",
      "id": "73f513c188db3a54ae3cc3993b2810325e6125c9e17e1982826c93c0f6924ae4632e3170a1b139c6b4cef5f7c1f5b5fc18f5b45e4ebfea6122cf03dcfe229470"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "ERK1 and ERK2 cascade",
      "id": "b26b7d573b6c3ea532b8cf0fd8515acf653d19cb31f0ffefb016871bb5657c4da7b1c72c64df231d7c528ddae3f97ae015efa5bbdeca2b05364c1a452ced499a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "acetylcholine catabolic process",
      "id": "24e6a6ec683674035e895c0c16f2960772967179fd8fe70942337a01550523ccb39e220fb055b90e0cecce823477a804da576ea67b38493449af6e12cd9025d3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "apoptotic process",
      "id": "1c5172472cbecf29eeb8e86a4cac2d13123fe572356f00e2f98302422560bbda2854e3b1f8fdf85396655393cf5ddb42e0db210c3d3fc146fa358cc8d0ed0254"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "calcium ion transport",
      "id": "7c1debe8c5aa50112a2768a7f845bfa93e1a6d2b911259a74f85603b0bd6b85e9b5f7092e547476c7cd51d82f313134048069f3cc2600eabc1ec0b33e88642b8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cellular calcium ion homeostasis",
      "id": "42a8d177c58d690725010af3c0e8a132e8ba5f8f85cfa9378e2477ee4ee2a98a757a902b4d60f058b3654108c72e0e02e35967ca41b3956517f9226ef23e295b"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cholesterol homeostasis",
      "id": "851e3019d3895edf591fad76200ffd82292580c2342c9a8b24e7a259375e5d34664caccf7f434daee51a68074523a65fe95e1021c187a28e795abd26547bd119"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "gene expression",
      "id": "5b53a5b81397df7ab4865f1e5c95669c12fc1a941c3081e714fba895f56db6b8259045e6f1ce286d3839616c90bfbea883967a33fbc1f0f3bc3e0b093bf03b7c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "intracellular signal transduction",
      "id": "db8fa3f64d7d47eea064bcf0508f25f668019704b5f282562f0eea584b6de77b734d2b656d039ba29c6315d54bfad2c916d74bcf3a79f2ceeb79b2144d7a76d7"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "long-term memory",
      "id": "de64bd41a57dd3d1b89821bbd8bed1e2d510c7633a0ba0703a73d175dddb26e1ef6dd1e7cdc956929dc91258155b11d6e1892b1d1641bdcbd9da10224bdc71d8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "long-term synaptic potentiation",
      "id": "90aca567c87981f32f4001b6386423cf473ef52decf04004bd136ab80fd9088c2698b76c8baf740f8e282b107790d3c88130dc99225bab73b22516859dc4203a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron cellular homeostasis",
      "id": "d02a902e5bf121fa7c000ed8b5ad08348e134a9e5e23642d5a729812ec2d669a8780152991b626a8c20d54eeec0f4df6fe14bcbc3a3065201091b013604d6f99"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron death",
      "id": "ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "p38MAPK cascade",
      "id": "7b310efd9386f5d69d4025edcf3c14c538a4502c851c7fea593a8d2ae7c2bf5329c371b86a8e0b9aaedff56b0183f11dc658ec1e90ce82448a682de95103bfc3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "positive regulation of synaptic plasticity",
      "id": "050537bd5075eee0d80cf0fb0ffef9bde5982ad43aa3d08210f907971b9ed85d8eb4077a2e978f20841471f4d510b7f3cb6101d08c47d86d6ea352394b76e0ff"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "potassium ion transport",
      "id": "2d62dd54f74f3acc48a9387f299d6de6512cdbe468865cc488fc6609fce6b7b15777de1637f13454f389325a2bdc1fa1ebf5fdd3531c1400dfb6a41d57dab0cc"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "response to oxidative stress",
      "id": "436a31de7bd3b1e539910821e1366f5e3b2914a38e51e40497edfe37d38d4460558b4b251b2a91eba047246d3eb0861f7d4ee9f868cdcb8c10a8e8115a302f00"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "second-messenger-mediated signaling",
      "id": "6f1413f8f6b78a7cf41113d9fee2b2d71ca100a8af94b3de3d7698442d7c50b7b3322f0276e858f3e1b2c7153407bc26026a29e865febba11ccee97ff741bf1f"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "sodium ion transport",
      "id": "04be44192f10ad73931e612448141dd6fa4ecf7054cfa7bca4cdc65141dc8629b65a21e90a057e03faca04f23c539e7b08c6d804a26dc99033a4f08c6bc6e4fc"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, glutamatergic",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "aging",
      "id": "e656a7a9b8877eca28efc8bcece0149b9f17b643e48c2ae605fb3977fb925968220ed9a29a1649919bd2bdbfd43e6cd082182ead002a6eb840cd3f1e4f57d213"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cognition",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HP",
      "name": "Neurodegeneration",
      "id": "96f5a3bbd33a722b2760c6448efdaabb70ed3e96434c786a9ad70ca7eb89b9585204c9e8df72a4ab1b5c7f617a36f919bde50523c31467d62a4842b479ddd805"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Cell Survival",
      "id": "abeaa000ab588015eac485dd605b78602795a7e237f3b097d8148a27fa3ebcc7a221d318d0399960d9f10cf194fbc9c29f41a2a8ed8c332b09f4b79680170b61"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Synaptic Potentials",
      "id": "c9256d88b8541fa08c06f1160cedf20162a6c2630128fc621d3ec0b9a50b044bb8e675aa542d9d6bf77e5caf03d8cabf1ab435dda856a86c7227601c8e4557de"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Homeostasis",
      "id": "4005ba0474e31f712b219832e2520ad076ef1805dc6bca6ed8084b2b3689f7e5c8951877af20490e0282b13542acf842b0c8ed29ad81d7581c8e1200addf533d"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 40",
          "id": "2ca2eb795438fe9e0f24c1e9d332717de5e344ddfee00ce8df89c5b901d85db5994d6ffd383e40a90bde264f33e75b220476b3de86c89f0658bf281c872f0bb6"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "alpha7 Nicotinic Acetylcholine Receptor",
          "id": "24bfa0a4dedd705b999b510936aa1c989978fdeec807bf3046bd5178bd8e69ebbf2b1d2d2cd30ce5df8058656f59f497172cea193c9743a405bfb38be1aac50b"
        }
      ],
      "id": "55abdc2e627de2ddddc1c24d99fc3365c351036ed8aecb834fffbca0a8d46c8fe238517be52e2959f231955b6dfd543eb4dc941b32380f792901881fd3640039"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 40",
          "id": "2ca2eb795438fe9e0f24c1e9d332717de5e344ddfee00ce8df89c5b901d85db5994d6ffd383e40a90bde264f33e75b220476b3de86c89f0658bf281c872f0bb6"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Chrna7",
          "id": "507ee2a4a31335902e30c31717eb51a26ee9f31d8e015d2cc3beb6961c3c386edb03a4ac82b8c0c0ee38319e2f43609932215b67a7fb2b3e4a496eda6f99f478"
        }
      ],
      "id": "5d7b0352657008475fb7d3d96025ad47439e134886347bf9f114feb2450ea87422b28956a175ad8b389b8902c7febbe9edd2af356c38a18070dfc1f7024aae54"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 42",
          "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "alpha7 Nicotinic Acetylcholine Receptor",
          "id": "24bfa0a4dedd705b999b510936aa1c989978fdeec807bf3046bd5178bd8e69ebbf2b1d2d2cd30ce5df8058656f59f497172cea193c9743a405bfb38be1aac50b"
        }
      ],
      "id": "df522a91d4f1872e0e5d512aa2ab4533f4894281b0b3e73cec8287dc14f9924c2df90506effc836adcba4174a2a89b1b8ce6261e9b18cf131ae12499609c438f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 42",
          "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "ab6cedf236d6ad4b8cee1a22790e2b7bd0bb91318b164f8f5f63f286d85092af61c50e9e28b4f267b5212d7be34f722310822347de4682466026066eb6ce4d61"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 42",
          "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Chrna7",
          "id": "507ee2a4a31335902e30c31717eb51a26ee9f31d8e015d2cc3beb6961c3c386edb03a4ac82b8c0c0ee38319e2f43609932215b67a7fb2b3e4a496eda6f99f478"
        }
      ],
      "id": "a3be7b5885af1db761442d369f1b268cc791810f0ec51cc0c471cd38eb344f48fc81f7e9e63ae76172e835beaa23f1c4e96fdc100a4b57529cf7a7fcae040e55"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "beta-2-containing nAChR",
          "id": "8f35d745b8594a75cec26426602ac5b8c08996ff27c1e4d41e9076e42fc677a58125713403cb8c017f08a2b9bcf5f707f4177bba19dac41a1ef58a71432989cd"
        }
      ],
      "id": "6dffcc251892f723019867829c598be1ce8ed51f5dce26768ffc892ee865748f6123ee3c79464f64144bfc50393464723cd220eee87b6f4dbb378f5f46db8c1c"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "alpha7 Nicotinic Acetylcholine Receptor",
          "id": "24bfa0a4dedd705b999b510936aa1c989978fdeec807bf3046bd5178bd8e69ebbf2b1d2d2cd30ce5df8058656f59f497172cea193c9743a405bfb38be1aac50b"
        }
      ],
      "id": "fbbfa396caa38a25dba816cae8a0df2dade08f192727f8d57d3ddec4f1aba60b49dfae04066a3d7f01aa60b2e5965c46f88a17f0e0d720e338d3c650ab54784b"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "698076ac57583c5e4e28f41327b6194ae8c7ac9c32d2a97fb0d89fa441c64263d7e36996ef4644326939dcb6fde7177cf28da0f11c75a87d01c238b5b5460190"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "FLNA",
          "id": "23b2398ba3cc645c269dbef22001b74db5f0479aa7715309532fa1b9beccd5462f0f4cf45fe6d8bd2fad349fc0e459f6f137cce5d0cc3e6579854ce71b3b4c96"
        }
      ],
      "id": "5b28c96c8eefa2621ac0bfea29e1ad1045685396d00a1916031268e9a313b3343317520ce9804a6177a3815ffbeb05944eee33d4f8664794bf0dc11b323c72bd"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "8357c1828c09a0ec54af61d181d1ebf59a7aab25510ecc68252f54f264154b88a01a5b82b91fa4f0cbc03f1564c4f66fec744dec219b833b8aba47a5dd9fcbf4"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "c4a1ebb35bc0e677139be2bf0437aea8c9f5d871d08b98b0494d6c6dcc7b27e26cc586b6acd4fc534d72b3e9e3e84065671a8d93a837f19314c3b41708c2d7e9"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "Chrna7",
          "id": "507ee2a4a31335902e30c31717eb51a26ee9f31d8e015d2cc3beb6961c3c386edb03a4ac82b8c0c0ee38319e2f43609932215b67a7fb2b3e4a496eda6f99f478"
        }
      ],
      "id": "1712d6de25b8f46bd02be6fbb7f0f4d14f627fc1b487e59a12c1af38da866e376b71a43bd36ad3b60dcae7bebf98384cff05f2af136ea14199c07466ee10b4e6"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "RGD",
          "name": "Chrna7",
          "id": "558537edd623f47f442a028a059090fdfc4001eba09a09a5d2f3bf72ac00dd4c36ad8e7d12cc322bc35b7b8c70cf8e9eb47c295e777230655fff6463c7ebc675"
        }
      ],
      "id": "8043e6effe2d4f12996157b119a87ef52b72cbd89643c0173e7298a64a49f64f72222c60e26a11a24952635e7a580fcd92763714b1e738823a8f17c1b526c221"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRM",
          "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
        }
      ],
      "id": "891c0ffa962ef89d365b3cca747f3f12d4c78419f3e14b3a776d86aa6485ba26888a1dae8be82ff361468c0f5676a13c9cc00f7945acdd6781ccb95a74bcadd0"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "2222a5ec463bfd6eab47a47bce4e12fd35d35f8a588d46d34b07bb197a55eb4a56b6027d2e44099ae4ace59fe91b5f32af58d23c9592ff5d5987539ed46e55ba"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "nicotine",
          "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRM",
          "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
        }
      ],
      "id": "a8c865ef9f7f6c9bbd0b71d83ccbb8a60dba06051abcf47809e4737757866ebe628fe2df966654802553c54ff75840a7c0a47de9211d149ed060d84ec05b147b"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "nicotine",
          "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
        },
        {
          "function": "Protein",
          "namespace": "FPLX",
          "name": "CHRN",
          "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
        }
      ],
      "id": "755001b9784553af9df52f25761d4d597267afe4d5d8fb257e62b5589d2625063ca94672b56cf87dd40ac4cd9104d8fb9c1a9fb3afd996c5e197e651b892512f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "APP",
          "variants": [
            {
              "kind": "frag",
              "start": 12,
              "stop": 28
            }
          ],
          "id": "2d1d2e1f679089331779ffaa8bec9d4b37f2ca990011901215e628dbeb2a14ed8d7f1424de70f280d3f4bb377297f8a7b235200e0156fc71a4408d98db8d98e8"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "6e295c5f868e3204b88ecd9efca7f55f32e41b0da34081e1f702242329ddddde20ed2ecd6c963f9a4fe9d6a596bddbaa2ec5a07afe7cc3b174e617b030a184cb"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA4",
          "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "d4fd90112c85c79fe7510d181fe801440ce05ef1193b78089fca9732d1e118ae19ab42d218393e25a7f515dceefd26f86d0465e72ea9ec47542be18ef8ca49c7"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "bb42095b8f22b8a99a9f3183817950e51125de3a824eab4c344f1d6e44f571a749e8f65e5d9fa3098e9853d963c898ce2926503ec4cb04ff98c9bf5a98b1edf1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "FLNA",
          "id": "23b2398ba3cc645c269dbef22001b74db5f0479aa7715309532fa1b9beccd5462f0f4cf45fe6d8bd2fad349fc0e459f6f137cce5d0cc3e6579854ce71b3b4c96"
        }
      ],
      "id": "339d5a3990d8101089ae3390cbfcdb76386d670f17ab9f3b7b5c71493947a61f4a8f4f4b5e9ca9f67609483add9e93efcfdd7afd596c7dd3c96a8c610f69b277"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "nicotine",
          "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
        }
      ],
      "id": "d3180a6bc3c859d3103202ce1cda30ed31af17fc8090947ba94de71c5b114c2f88f6b10cb5b9392e58b4ea5770986a227f51c95fbf8a2b6616c0c0ce8957614f"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "simvastatin",
          "id": "ae75f3e4fc31e8a726708aec0f7d3023c153e2e7bb68fa993c0f311672f04fd2450bb7e0c8c5b335887f0452d795f262a80363bbe5b9b2ce07ce015d62935034"
        },
        {
          "function": "Protein",
          "namespace": "MGI",
          "name": "App",
          "variants": [
            {
              "kind": "frag",
              "start": 25,
              "stop": 35
            }
          ],
          "id": "1e89bfc86590a72a5b76e1019042cc0e316c0b374bff360d870dacad2b2bf8d70c0ac11efe2fb4bbd33b5e8b4a3810c8152c7f61317c9dd997df89a82018266d"
        }
      ],
      "id": "8379bf889a2d6eed2faaebe7b827a2daee0ed89da8f208542648c15af34c0b0d076c0fdeb97c24165fbeae5a6dd7787421d2c38c3684e04d79fbd1103bb653b4"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "AKT",
      "id": "3263678a1e320013081e7134e7e64e91b2c66e6fbd10dd7fe4fd282cf0cc3ba29b5cacb5e8eb0a8ac0a194f73b80dabcea5465b0fec5b044290b259ba889cef1"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "AKT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "e0ee1c0157a2e80e92de9745508ee6e818136d101d39c7f9a2c0a61ce4155bb1dee984ecee4d3f153cee55b87c5821b182f32bf6c394fb20beb507e6b337499d"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRM",
      "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRN",
      "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "GABR",
      "id": "35ecfd9221991026addd0bf5117db421d2fc3d002170d78efabfa239f8e0593cb37801f334c65c051bde3aa68a34e6f7942ca111a624c5362ed0e761b338c465"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ACHE",
      "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "variants": [
        {
          "kind": "frag",
          "start": 12,
          "stop": 28
        }
      ],
      "id": "2d1d2e1f679089331779ffaa8bec9d4b37f2ca990011901215e628dbeb2a14ed8d7f1424de70f280d3f4bb377297f8a7b235200e0156fc71a4408d98db8d98e8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA10",
      "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA2",
      "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA3",
      "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA5",
      "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA6",
      "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA9",
      "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB3",
      "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB4",
      "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "FLNA",
      "id": "23b2398ba3cc645c269dbef22001b74db5f0479aa7715309532fa1b9beccd5462f0f4cf45fe6d8bd2fad349fc0e459f6f137cce5d0cc3e6579854ce71b3b4c96"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "id": "78d5e866274e31ff2b09ef6663cb084c62dad139135478daf1645a32988a8214b14330f44be626991077159244c9e35920dcc0025af376746275c215fceafca6"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "variants": [
        {
          "kind": "frag",
          "start": 25,
          "stop": 35
        }
      ],
      "id": "1e89bfc86590a72a5b76e1019042cc0e316c0b374bff360d870dacad2b2bf8d70c0ac11efe2fb4bbd33b5e8b4a3810c8152c7f61317c9dd997df89a82018266d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "App",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Lys670Asn"
        },
        {
          "kind": "hgvs",
          "identifier": "p.Met671Leu"
        },
        {
          "kind": "hgvs",
          "identifier": "p.Val717Phe"
        }
      ],
      "id": "a36c453fd5633ac24aebbc1d365797e09e075d6f0da585bc4d95ebc23bdb3da51ba51e12d410720f2614cf5197b0a7e1f497378c24dddfe1106e26242066be3e"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Chrna7",
      "id": "507ee2a4a31335902e30c31717eb51a26ee9f31d8e015d2cc3beb6961c3c386edb03a4ac82b8c0c0ee38319e2f43609932215b67a7fb2b3e4a496eda6f99f478"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Chrnb2",
      "id": "43a607401c5b2bfa4185b8cb7ba14e4eabfe8f0a599cbe0ea3b10c6f9ba7b20d832f3d5f471829b39e89c53f5d90dd47e37773a62910aca6d39c6d00f82c09e2"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Map2",
      "id": "fcd026576f82ae9f7a8a42557aa2d8603dded049aba59024d2ff779397b3a8d6183a357b84433fc0b9918c463756cf9b01c93f04720bb0af24ee3fb8f520624d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Syp",
      "id": "81f5125d4b52aac9a857be32b63ec0cfb4206764335f8942e31d07bc0d579e8dab81cc419d387f2d6d3913d6b219d530e68d5199d0106174a91f1824a212a736"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Chrna7",
      "id": "558537edd623f47f442a028a059090fdfc4001eba09a09a5d2f3bf72ac00dd4c36ad8e7d12cc322bc35b7b8c70cf8e9eb47c295e777230655fff6463c7ebc675"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "mitochondrial dysfunction",
      "id": "290f620a8ca62af5c329ceed61c52205bedef0b2ba17347a57e3e26dec8a12aac110be32f0fda6061476b9745f37c4e21a45fe75b71d678f32dc6ccdf5362edd"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Cognition Disorders",
      "id": "43422cbce58332f9de0fad425a85437caaae9bda4848ed4e20f1457b900029d28d1983e193feb851085642fe9280a8338424746eb3afb8b094942401f9a0c969"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Memory, Episodic",
      "id": "1e3c1dc405e08e0a9a500a8f1a97ed80d71732d86f0816e51acb9caf5ac95cb217165824ff6133d61bd1a5ad2ecb08fdd2f4ac4911a5193c67e30e8ab003ffb8"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Plaque, Amyloid",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Spatial Memory",
      "id": "7617bc77b1deb949824e3cb1b4d2c858cd784ace0d2c41934e19bdeb43b399553629ec153ef25e9e2c80d2389dfc60de193a290e2fb966544d5769aba98f1358"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Dementia",
      "id": "64388ba3ecebbe4d33fb76bedff9f458276b3ae72f47d401c6852d7f9d7c2abf4b2c4cfb899133f8c6ef9f7eff00a84697a1719fa10fed2e67ec00e97d00ed65"
    }
  ],
  "links": [
    {
      "line": 88,
      "relation": "association",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 56,
      "target": 123,
      "key": "4c8a101299120b251c3845d083fb2954db5c97a7e1a0064772776cdd982a4112187ec21c6a95569d6d07392a3d32091f9a339316f03332a36abc272ff2554d6d"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 123,
      "target": 56,
      "key": "d1b1c861a9396d55dd0188806da30904a8d10fa2e51dade309549c700c8d04cd3f0c13d77f8b39587c4567b64e70478a8449fde563312d974896855c2509ea5b"
    },
    {
      "line": 89,
      "relation": "association",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 123,
      "target": 117,
      "key": "85e5f42bbbf8cece80175f9db9ff0176b6460fdf382549fb8a3bfb702b4f27ce06b230c3e95e9aac40dd62509239d0438c6df21bd9155f4aaec24206eb90f41a"
    },
    {
      "line": 89,
      "relation": "association",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 123,
      "key": "55acd487426ab0bacb51a0ec10d53bef2372d8f6993b841410eccb2924fee75c69e4f12fb739428577a201d859bfcff85a0b640d4fdd2e3289bfe297603c5fd3"
    },
    {
      "line": 90,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 120,
      "key": "22996f1eb252ad9e93deaadca6088a578fdb8680cbb98546339e0c48ec1ce388349fd0412daa965ca402a0acfe30cb223ba78478fa55f49207f033c5de0da331"
    },
    {
      "line": 91,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 107,
      "key": "25f5dec77f38590fd24335b73cf6d7799115b59af1bf735a6b21dd1cbf602056e1e69046206d00812f1b5a8dcfc7e2326110861cbc4f1e5879ac35f4c94bb893"
    },
    {
      "line": 92,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 48,
      "key": "246845fdd37c00fc31b824cc9db2d6376551f510a0e6d261e5b125b85db48417a5cc1a656811e0c631213ccd761c2e6091b255a014862b8d1d902cf102d40e15"
    },
    {
      "line": 93,
      "relation": "negativeCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 12,
      "key": "2a629c2db5abce8b885b1f5b6e2d669d252845836eaf8bb19c88a3f7a2f74b9f3ed088836d00d79f801c53d14fac43fecc64963e920b7713367a0ea3e3e6e394"
    },
    {
      "line": 100,
      "relation": "negativeCorrelation",
      "evidence": "In addition, anatomical studies in AD patients showed a massive loss of brain white matter and a specific reduction of cholinergic neurons of the basal forebrain (Auld et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Kim et al., 2013; Whitehouse et al., 1981, 1982)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "source": 117,
      "target": 31,
      "key": "101090643948ea48efc3c35ec5473aafe7f1c0dec115336e50fcc872ad00628b3e4a20edaa0fb2d27efc015ef989fd9f7a32fb7afbdef59adc64e35b95fb5805"
    },
    {
      "line": 102,
      "relation": "negativeCorrelation",
      "evidence": "In addition, anatomical studies in AD patients showed a massive loss of brain white matter and a specific reduction of cholinergic neurons of the basal forebrain (Auld et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Kim et al., 2013; Whitehouse et al., 1981, 1982)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 117,
      "target": 24,
      "key": "9a6152b2f2cff70b6c28f5ece7516e6e1e0aeca8029c08416ac057689a00887953759c47f219507f89a158046167b65a6c21d91e77a046d5fc6b067b6a6f95a8"
    },
    {
      "line": 140,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 77,
      "key": "345e397d2be6587205ae218c1759aabff5f58a555ad5c08e673457ba0fe1ea8d8bb413ade0f5e69626ab1f3cc80e17b613ba237588bfe432489fcf20c717a2df"
    },
    {
      "line": 141,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 76,
      "key": "5af06b028439e86b2cb4f178721b886b3857e0e83b4b4e24f42011f4c386f4e5b78b80d6ebe9f60b1d3fe50d90787901bee8ff5b965f5a624b25e96119f7b914"
    },
    {
      "line": 142,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 79,
      "key": "9a45e0948fd8512b1ef0304697713a0154bf3be65a2140ab1f48dbe6e93eea0ac33e7814b173f6fb5d8d2b44660d05c17c322ced67df53d39627f4f4bf455cc5"
    },
    {
      "line": 143,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 78,
      "key": "82ceb98c663a3677c72be7ffef280fca2c63ce9827d01beb7dd98216cd19637159c03a30cf77d4ec343559a8bfd866cb413c21d38b6f0b42e8748d6f63a9a6e5"
    },
    {
      "line": 144,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 89,
      "key": "3b5adaf4ba17518ba0df0c985119429f4210f6e903795be07fce8f969bdddb355b00b54414ef3af3f5a58e3d3d2180433f08087bea8bf44f60f089d863083407"
    },
    {
      "line": 145,
      "relation": "decreases",
      "evidence": "Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; Whitehouse et al., 1981, 1982, 1986)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 117,
      "target": 88,
      "key": "8769f68e6e97d46051d559ea7e4136a4997a5bba75c42183880ad07332bce27f250e8ba998f3a3e7eb6ad098d6df30b57be9a6fc124038f4711bb66113802283"
    },
    {
      "line": 154,
      "relation": "decreases",
      "evidence": "In addition to nAChRs and mAChRs, the enzyme choline acetyltransferase (ChAT), involved in ACh production, is also affected in AD. The activity of this ChAT enzyme, and consequently the synthesis of ACh, is decreased in AD brains",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 117,
      "target": 94,
      "key": "76b76b8e01215f098913104e245c933c4fae025a3a6aee75f4bf64d161e1b46c281156f39bcb1eec633ad82118b9976fe76026edd918121d43767769aaaaa470"
    },
    {
      "line": 155,
      "relation": "decreases",
      "evidence": "In addition to nAChRs and mAChRs, the enzyme choline acetyltransferase (ChAT), involved in ACh production, is also affected in AD. The activity of this ChAT enzyme, and consequently the synthesis of ACh, is decreased in AD brains",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "source": 117,
      "target": 6,
      "key": "9f5284cbcf4c4bc0b5da63859d7624927d0987c9d5cca0f13c7b9d4825ad8bb5aacf2bde8fef18f0dd5874b9532c728c65cc101bbb2aba6817544e3b1a93db37"
    },
    {
      "line": 537,
      "relation": "positiveCorrelation",
      "evidence": "With the progression of the disease the amount of Abeta increases, it starts to accumulate, and becomes toxic for the neurons (Hernandez et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 117,
      "target": 3,
      "key": "f99ef920403716bde6b0601b1a7bd181bd277811f9f30f452a2b5f465b0285874dc1a57609bfe445609756d0d3ee678701c631e4591e61f1f63a97fab82631cf"
    },
    {
      "line": 538,
      "relation": "positiveCorrelation",
      "evidence": "With the progression of the disease the amount of Abeta increases, it starts to accumulate, and becomes toxic for the neurons (Hernandez et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 117,
      "target": 21,
      "key": "e782dcad229a94e6d0bddfe0a7598a5c9bac6f4f11024ad3e3c86737ad1741118b67ba20e21b2ba1668bdcddd021c83225ee7d2065e315662594463fe37acbc9"
    },
    {
      "line": 711,
      "relation": "positiveCorrelation",
      "evidence": "Wang et al. showed that the association between FLNA and the alpha7 subunit is elevated in AD samples compared to age matched controls",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 117,
      "target": 83,
      "key": "275f16ffc8a9a2ebde11babb37576af31f8c51a5cb6aea7d5ae038a3de00f25b04c7c43eecc4f9be5d1c0579106d1cd086b9c1a6944bd1d3658e839a49f2fbea"
    },
    {
      "line": 90,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 120,
      "target": 117,
      "key": "09e7a139109ee79e7fcca6298600897e4043bc967bdc23c66d71755f005e73263f018b096f87e334d2ea3acc4200bc391b3bcd102f7cee68a4917fd30cf873c4"
    },
    {
      "line": 283,
      "relation": "association",
      "evidence": "They showed that alpha7 subunits co-localize with Abeta1-42 in senile plaques of brain slices obtained from patients that suffered from sporadic AD",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 120,
      "target": 66,
      "key": "79ace0a09551975b01b035156255554239726679bacbc326f4e4ebf2522d8a80f0be0442874c3c3fa4d56f8c3103249fb2dc124e0bcf7af399db834ef91388a8"
    },
    {
      "line": 91,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 107,
      "target": 117,
      "key": "e17daa3943838c2fb68d95fc174f95e34a55c50acf7ce0129f7eef16f4a03b84d7fd799f2a907904e1f6c720f74785f7fb9ffd371be90ffad897edd1702e1ee6"
    },
    {
      "line": 92,
      "relation": "positiveCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 48,
      "target": 117,
      "key": "ffb546cb58f1c61b1ae267d4023532a6385f99ba2847e27511d63f28678f1d801c4198d74a797b4e6a5c8bd67301a7aa28f7045225d065c2303dd33b428ffad1"
    },
    {
      "line": 93,
      "relation": "negativeCorrelation",
      "evidence": "Dementia is a debilitating condition frequent in ageing populations, and Alzheimer's Disease (AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological hallmarks consisting of an accumulation of Amyloid beta peptide (Ab) in extracellular plaques, intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic loss was identified (Braak and Braak,1991; Masliah et al., 2001; Selkoe,1991; Spires-Jones and Hyman, 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 12,
      "target": 117,
      "key": "9a666ed22b8577f0179cba3b2ca9e6a53c7f5f6e62fe06f0881f795b21dac1f72ab17f33ce18fe70b62e224137fb43be99a0a829ad7389545b5e29ba2c5c7ea3"
    },
    {
      "line": 100,
      "relation": "negativeCorrelation",
      "evidence": "In addition, anatomical studies in AD patients showed a massive loss of brain white matter and a specific reduction of cholinergic neurons of the basal forebrain (Auld et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Kim et al., 2013; Whitehouse et al., 1981, 1982)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "source": 31,
      "target": 117,
      "key": "863c1d678c14915b44cde371f94ad5ce08784c397d9f8df3189f437ed2d989d43aeb848de095ce8406af79a6311355529528ca1ca39a694a348a869576c813a1"
    },
    {
      "line": 102,
      "relation": "negativeCorrelation",
      "evidence": "In addition, anatomical studies in AD patients showed a massive loss of brain white matter and a specific reduction of cholinergic neurons of the basal forebrain (Auld et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Kim et al., 2013; Whitehouse et al., 1981, 1982)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 24,
      "target": 117,
      "key": "85e6c0564fe3db5c9db7fef1d1c8409a6d72598d25321580c5c4c8cc5946dfdc5d281614c72a80f1f416f933f3857c38f9538edd04b9003fe56e7ed94e709f80"
    },
    {
      "line": 106,
      "relation": "association",
      "evidence": "Several studies demonstrated the pivotal role of these cholinergic nuclei in cognitive functions",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 24,
      "target": 57,
      "key": "748ce208045eda2332be622c43861ac7fa4823ae335764fd5913ce35f2cbf7910667ed0c1af966eb53ecc845e70f505653661855b2f21596a4818ae5b3adc13d"
    },
    {
      "line": 172,
      "relation": "increases",
      "evidence": "The role of the cholinergic system in cognition and the modification observed in neurodegenerative diseases, and in particular in the case of AD, led to the formulation of the âcholinergic hypothesisâ of geriatric disorders (Bartus et al., 1982; Contestabile, 2011), according to which the reduction in cholinergic innervation is responsible for the cognitive decline observed in AD patients",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 24,
      "target": 57,
      "key": "c2a883a0a3faf8b20d3c818cea2b53d57f3dadccfcb4e3b9ddc2442774266a121742cf55ce6c36455e6e93d22505fdfae2a9f7b873a287b716ca3c4d02937e2d"
    },
    {
      "line": 115,
      "relation": "association",
      "evidence": "The cholinergic system is also involved in attention processes (Muir et al., 1993; Sarter and Bruno, 1997; Wenk, 1997)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 24,
      "target": 122,
      "key": "395015a6b9606f6ac4ff8136bfd0bbce3dd7a319d28ba455d66086fc9a1810d0bc2e67f2e3792b81fe24df2e9a4c99c6e8ecea73a73d03ed2b6216a11b9a89f0"
    },
    {
      "line": 106,
      "relation": "association",
      "evidence": "Several studies demonstrated the pivotal role of these cholinergic nuclei in cognitive functions",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 57,
      "target": 24,
      "key": "91ca60dd09384d9d9e7782054003f4184f67a68cbce1841596d6be4d5cd0a17a334d89e9bfba7aa31f70479a7b4d59d03d33fae7e2c093fa74a3ddc0a85f869f"
    },
    {
      "line": 111,
      "relation": "regulates",
      "evidence": "Woolf (1998) proposed a model in which acetylcholine (ACh) release leads to the modulation of cortical circuitry that finally encodes for storage of long-term memory",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 6,
      "target": 45,
      "key": "c03497a9c84b57b6c620085b7f6d6f41e8af9b9ef93a508828f94c8c10a745ceeccf4993268efe795077695d9f88c4f8c0d4e47d71a1c515c6441ebd28dd4347"
    },
    {
      "line": 268,
      "relation": "increases",
      "evidence": "Aged beta2 null mutant mice have a thinner cortex compared to agematched wild-type controls (Zoli et al., 1999). This work should be pursued further as it indicates a âneurotrophicâ action of beta2 receptor activation by endogenous ACh (Zanardi et al., 2007)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 23,
      "key": "98cec85a7c830c0be38c2ad2a7d36becce0b78e98da396b25e6686d8d62586369a479890f768c1cf09bf38958f0a99c9f366fd7dc0ce3cc1494308109db86515"
    },
    {
      "line": 380,
      "relation": "increases",
      "evidence": "A different set of experiments demonstrated that Abeta enhances ACh activation of the alpha4beta2 nAChRs expressed in oocytes, this first activation of the receptor was followed by its inhibition (Pym et al., 2005)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "Cell": {
          "oocyte": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 17,
      "key": "76179fa094ccb9e5200feba48201d824f8307987fa60c1ee707dd3e7b7582284e26f3a0acebe08df8fbca0e9e2888216bbe0cac10717b4f4dfec68422d99c26a"
    },
    {
      "line": 115,
      "relation": "association",
      "evidence": "The cholinergic system is also involved in attention processes (Muir et al., 1993; Sarter and Bruno, 1997; Wenk, 1997)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 122,
      "target": 24,
      "key": "f5c923004bdf56c0748274c1f70e0bc7d8aa0f04bf545dd698df17cdf2087b46301fa6a595b2a7c80ccac366849c577aa8fa9b9edca952fe7cddbc33b4468caf"
    },
    {
      "line": 121,
      "relation": "increases",
      "evidence": "In a mouse model, the lack of ACh receptors in the prefrontal cortex (PFC) was demonstrated to be responsible for attention deficit, restored by the expression of the receptor in this area (Guillem et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 27,
      "target": 122,
      "key": "48993f3832f8930e155c9a518426f7b0633888057172a5d18a6334d6d50929454b403c06abf533b3538b0d73d19a999ed406e79f34416dbf5ddfb3cc05ca9baf"
    },
    {
      "relation": "hasComponent",
      "source": 77,
      "target": 6,
      "key": "49e906314013e6f6d4b8579e38908da55678d1272581c82ebe922e0658844f49cc1aaa4ed6a8f840cfaccd80040bac0ff7228359f4da6f4e5f6884b3d8ff41e1"
    },
    {
      "relation": "hasComponent",
      "source": 77,
      "target": 89,
      "key": "64d3c87f770890c742046ebf63fa93813811aa994a9435305d565cf7c25ee02e8a00bcb8f4a82270f62680a8a27682df9b8dbdf27099bd0fcb59a117fb846770"
    },
    {
      "line": 130,
      "relation": "regulates",
      "evidence": "The neurotransmitter ACh binds to two families of receptors, nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs). Both families of receptors regulate the cognitive processes mentioned above (Ghoneim and Mewaldt, 1977; Petersen, 1977; Sarter and Paolone, 2011), and are both affected in AD",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 89,
      "target": 57,
      "key": "9f57c755a7bac20a9fc80e701a9cbab7dd876e3673ee7297a65139aa81efc9d70cf165984ed8a28477d80be32e65724b97d01d46024ccdb6f70fb50e662e01bd"
    },
    {
      "line": 179,
      "relation": "isA",
      "evidence": "Nicotinic receptors are transmembrane pentameric proteins that belong to the âcys-loopâ superfamily of ligand-gated ion channels together with GABAA, GABAC, glycine and 5- hydroxytryptamine (5-HT3) ionotropic receptors (Changeux and Edelstein, 1998; Le NovÃ¨re and Changeux, 1995)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 89,
      "target": 26,
      "key": "2af6c48bcea12fff4469615cf943dc3e91ccae024e780876c8682596aa43ccb352735c649254386635410602de63bba608efaf14835d0731e6cec2952b8fdd0b"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 96,
      "key": "19d134eafe8dbd446db8540aaaffb08974f941a5c8d8cc922e4a3529ee64c384866eadfb7f778244d0c158e7493031ccb95f69d2731b6751a92925992a2603f1"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 97,
      "key": "5c23615e6b87547d31f083263bb6db6fb9708ac5877d8d8709ad07c8ed6b25ed046e20f606cbb60a2dc11862f31e2b5f21388d3bff3f49c16a433d171e8364b0"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 98,
      "key": "572eae1f9437faf87aa9a7faf59ca4f6594cfd4bddecde3589dd9490c4e6321f60840b439dd6abdbf8dd515a99f5c79986a0973542b5d3e911135428bb7741da"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 99,
      "key": "fd87701c9d29a3cbd2e5f6558bfabc96183b60be0350396954ffadc58aae45e59c33a89baab051ccba476f4df603158bf5a316f8cf6e2be10ee67164d147e2b1"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 100,
      "key": "b3175e39190fd1ae45a1c34cee7c24da29e5402d0e90275c1a6bd5e7eacf88e30df23b26f74bdcc35497ea8ac62f803b66277d3aee9b721f24aa7a7051be69d9"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 101,
      "key": "ff7283f4e01982f2422f09905fb8aedba4d967116a4ea2b7c4a2ee7a44ef8d52d06f950e0c95ebd194b6323f960caa5aa3f76f2e5edcc3b9a49bdc8c32e006a0"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 102,
      "key": "bbdc30e8ea1a8f0531b46d0ca888f39153e0fe76a0c62eb9d810a6f185f2f8aca41aea1aed631ede77015791d40b3871ef24b36d2a2f589d26f8ea314c9c4769"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 95,
      "key": "f2ef3b5bba07a4c598305ae6e787fc91a0ffa5bd4b39e90d4e3a45b92ac26c10dddc5acda37b97b01778a9c0a354904cd0add45a17b1004e606cca4876bb0cf6"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 103,
      "key": "d8b5cd28e31dbad32db5ba0aace00d993eafc71c8eda248f44d9f2a8934191332a4b6752a7236c7c5e4b8aaba3c1bd1e99f6c006861eb1941c24ccf81c4a8b31"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 104,
      "key": "d719dfcd47550a03a543b92846758bf2e7362df027b706158dd5273d1ed0778ee23a33c1875ad74ef3925c0a75018a72c1245351049215585f3cfe51282baf05"
    },
    {
      "relation": "hasMember",
      "source": 89,
      "target": 105,
      "key": "cd27110413cfaae5279f0823c6d8405d1e0c7cc569809126cc3cd5a80c6973dc654cf5c6edb183f48389c751b0dc2a338d93bc247db2b4d35ef30f8fa63bc398"
    },
    {
      "line": 191,
      "relation": "regulates",
      "evidence": "The five subunits that compose the receptor are assembled around a central hydrophilic pore that mediates the flow of the cations K+, Na+ and Ca++. In the human nervous system, there are eight alpha subunits (alpha2-alpha7, alpha9, alpha10) and three beta subunits (beta2-beta4) that assemble in different combinations to generate a variety of nAChR subtypes with distinct electrophysiological properties and brain localization (Albuquerque et al., 2009; Gotti et al., 2006b, 2007, 2009)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 89,
      "target": 51,
      "key": "1bec10c6b6ff7d205df17766c28de0054387f58d5bfb2e3c0620988f104cfcb736d2e7819f4c1c214187af51fea556a94f7c53b91220b865e3b9873b53d55417"
    },
    {
      "line": 192,
      "relation": "regulates",
      "evidence": "The five subunits that compose the receptor are assembled around a central hydrophilic pore that mediates the flow of the cations K+, Na+ and Ca++. In the human nervous system, there are eight alpha subunits (alpha2-alpha7, alpha9, alpha10) and three beta subunits (beta2-beta4) that assemble in different combinations to generate a variety of nAChR subtypes with distinct electrophysiological properties and brain localization (Albuquerque et al., 2009; Gotti et al., 2006b, 2007, 2009)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 89,
      "target": 54,
      "key": "96dc7d0cbc1b60b400281ddfdf7852e01ad8d990904b85a594d85e27e60e2b6be5ef9bfff935c9073d8e25e0cedcb0c898da4d7cf76ea3fa70f9fe8ba3214bed"
    },
    {
      "line": 193,
      "relation": "regulates",
      "evidence": "The five subunits that compose the receptor are assembled around a central hydrophilic pore that mediates the flow of the cations K+, Na+ and Ca++. In the human nervous system, there are eight alpha subunits (alpha2-alpha7, alpha9, alpha10) and three beta subunits (beta2-beta4) that assemble in different combinations to generate a variety of nAChR subtypes with distinct electrophysiological properties and brain localization (Albuquerque et al., 2009; Gotti et al., 2006b, 2007, 2009)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 89,
      "target": 40,
      "key": "2eb38ad70fa7dd88ae7b8c0d25fdefbd75c2ec656aa734ed5a0530456b431ca5d6e171ed52d25c4d1b2bb8e54de159f2fd0c8edb2e42902b0f9393de457c167d"
    },
    {
      "line": 351,
      "relation": "increases",
      "evidence": "They demonstrated that Abeta1-42 drives a reversible inhibition of nAChR-mediated currents in hippocampal GABAergic neurons recorded from rat slices. In these experimental conditions the most effective Abeta1-42 concentration was 500 nM, but inhibition was found also at the lower concentration of 100 nM",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "GABAergic neuron": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 89,
      "target": 61,
      "key": "9286e3453979f88d7e05bc314aa8ca7254d3ccaf15a70f082128ca5ecbeefc1ad472ece95901f802590f68d1a20d34f1d0bffb7c1ec80618604f749d9b30489a"
    },
    {
      "line": 497,
      "relation": "regulates",
      "evidence": "These experiments confirmed that the level of expression of APP and the consequent synthesis of Ab were comparable between mouse lines, demonstrating that the difference in cognitive deficit and neuropathology were mediated exclusively by the nicotinic recept",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 89,
      "target": 118,
      "key": "a05b2b3f396f9c9b4bf87c768142c1d69c28c4a8bc85171408e331359e6021172bd65d281a4022bae46109ed4b157e70e371fa4d279b27f0392e9aabc3627430"
    },
    {
      "line": 620,
      "relation": "increases",
      "evidence": "This kinase is sensitive to Ca++, whose levels are increased following nAChR activation (Oddo et al., 2005)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 89,
      "target": 4,
      "key": "3a6a4d3ac231ad9f9674a06523949ce90db00f87d064f2f6b06611d0f9888a108745cfec6bef6e40775209b597d204cc92ad75e6bf06554f41d52d2600ec59bf"
    },
    {
      "relation": "hasComponent",
      "source": 76,
      "target": 6,
      "key": "d89aae32abf9d4241edbaa204229c74a0581982a3c74558d4e46a696725cbad8dee3f43968863169aa5bc3cf3e29cea1d1858327951c3cbe123f0392f7191293"
    },
    {
      "relation": "hasComponent",
      "source": 76,
      "target": 88,
      "key": "13d5a319c77b1c0eb4fa7a7d147537f3b29e9f2e3568e4cc40b51cbb41692a89021257e613883107e1dc8c7b2541df432bd06c454808a33e19a39012da3706a8"
    },
    {
      "line": 132,
      "relation": "regulates",
      "evidence": "The neurotransmitter ACh binds to two families of receptors, nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs). Both families of receptors regulate the cognitive processes mentioned above (Ghoneim and Mewaldt, 1977; Petersen, 1977; Sarter and Paolone, 2011), and are both affected in AD",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 88,
      "target": 57,
      "key": "4f3e830cb89120f3180e82fe23f35ad5692f3c1047c574aef4c49ecfb20407b1425888d5c4055c8a34c42622748b591a06fad682f2b96849b779ff0defb4b241"
    },
    {
      "relation": "hasComponent",
      "source": 79,
      "target": 9,
      "key": "4145f82bce1562f0e44acefd4c607265879e345771c4f14d44a36db979ad42f20c8b3c569051823d83a397794b823e6040a982a25b09d87ebaac9d73a120d1bb"
    },
    {
      "relation": "hasComponent",
      "source": 79,
      "target": 89,
      "key": "3069ebcfcb2409924fd49c3ea4ee7f506d68e231cf68bdbbb328b98148d959af12e844de219b438e7355508bc6d19bcd83c8f911248cc1b3b93a140f6461ad46"
    },
    {
      "line": 430,
      "relation": "decreases",
      "evidence": "Akt phosphorylation mediates the downstream activation of an antiapoptotic pathway, which is also activated by nicotine treatment (Kihara et al., 2001)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 9,
      "target": 39,
      "key": "8ecf04aa4c0c7e31c976f1b66a225338b9b3fd982674cbdf217f286300ebeae3e9b8ca3697fa6cc4c0dcece1f3174c43adad0b27fe398dad86c4fde42550c07c"
    },
    {
      "line": 565,
      "relation": "decreases",
      "evidence": "The analysis of the Abeta fraction reduced by nicotine showed that mainly insoluble Ab1-40/42 was affected while there was no change in soluble Abeta (Nordberg et al., 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 2,
      "key": "e718173c69218f4c024474dfd8efc8a900d24f91033c96316c03d7f462295e4c8418bf6b2e97d58bdf86f2394437eae2f30ca5a4f629408edde781510b13f357"
    },
    {
      "line": 570,
      "relation": "decreases",
      "evidence": "The short-term treatment of 10 days showed a significant reduction in cortical insoluble Abeta1-40/42",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 2,
      "key": "889605dcb4cbed2bc21f361b4a0d4931b8524428fe138fbbd7675764e974e6e32aca835728de9c8e360c60bd374f06cb1a3ff58ec0b8fdb33666889d4471ec63"
    },
    {
      "line": 566,
      "relation": "decreases",
      "evidence": "The analysis of the Abeta fraction reduced by nicotine showed that mainly insoluble Ab1-40/42 was affected while there was no change in soluble Abeta (Nordberg et al., 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 1,
      "key": "9b7fd346e8d0c6a32a1311db0ffd33243923cccd7b367d9c45862109bdf5f9019e69bb850f2c0e05010d9e38914d1b7ab244f2ffdadf376c44c854778b40cabc"
    },
    {
      "line": 571,
      "relation": "decreases",
      "evidence": "The short-term treatment of 10 days showed a significant reduction in cortical insoluble Abeta1-40/42",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 1,
      "key": "f6f5339aaa6ab3756c3d25137932f9704266f87f1663ae4a14dbc10b4350e1e321877bbff55f215a1092350e09c279b1f72daa6dc278bcbef7632a4dd41cb22f"
    },
    {
      "line": 575,
      "relation": "decreases",
      "evidence": "Long-term nicotine administration elicited a reduction in Abeta deposits in blood vessel",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Blood Vessels": true
        }
      },
      "source": 9,
      "target": 3,
      "key": "2b675c6ad8152f29b712153448fa870e61333a449e8d6f5330bee0bae6098fa91ed435a194a8702a0e7a5a0cc2c9e966538ba32cde60b71a0c76ae11241cefb7"
    },
    {
      "line": 583,
      "relation": "increases",
      "evidence": "APPSwe mice at 14.5 months have fewer alphaBungarotoxin binding sites, while in transgenic mice treated with nicotine the number of alphaBungarotoxin binding sites was recovered and comparable to non transgenic age-matched control mice, suggesting that there was an increase in the population of alpha7 nAChRs (Hellstrom-Lindahl et al., 2004)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 32,
      "key": "70fa506534938df6309c008eda796c2de46bdd6d5cf990872fc615d929d74733f69251e050e3b771860d83ff4ddfef54c31a67fd24ca7f2bace8e501f60b4743"
    },
    {
      "line": 602,
      "relation": "increases",
      "evidence": "The explanation proposed by the authors is that alpha7 nAChR activation through nicotine binding could promote survival pathways and recover the synaptic damage caused by Abeta (Inestrosa et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 32,
      "key": "0ac1cd66916f5a94db15774f9448c2706d0b2a30b770c23be451edbd28167a110085c1478582af509fc1c5582184b16b5351df9d13cd0fea3a0c235b291b634a"
    },
    {
      "line": 633,
      "relation": "increases",
      "evidence": "Nicotine treatment improved the memory deficit, highlighted with the Morris water maze task. Surprisingly, this study showed a dose dependent increase of alpha7 nAChR, a result that is in contrast with the literature (Oddo et al., 2005)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 32,
      "key": "a94f76d68a70a2ee05c73dd9009496affa72d123fa9ab8fa9677db6c4c4ed8ca96122d8e6be1be8e199ab700827756568b0a0625574998fe1db8825541544724"
    },
    {
      "line": 589,
      "relation": "increases",
      "evidence": "Mice aged 6 months were treated for one month with nicotine injections, which led to an improvement in working and episodic memory compared to non-treated transgenic mice",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 119,
      "key": "95714c11ebf8983a41e3052eeafa1463751c839e7e8f7e31d50a23455a163a8b2de713df077e34a1a25320ec03c0eac447afbac95eefa0d0f1460362db4a2f6d"
    },
    {
      "line": 593,
      "relation": "increases",
      "evidence": "Like the young mice, they also displayed an improvement in spatial memory, demonstrating that nicotine enhances memory in both young and old mice",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 121,
      "key": "b64f1f336ac33acd4e816f86cd6c9de5605909571bf52eb0ec31e9fb2b781f0c9fdc7db6031f5191fb4620a33eb454c4a8b9610a378a0f5a4529f79c66231fad"
    },
    {
      "line": 597,
      "relation": "decreases",
      "evidence": "The amount of Abeta was quantified, and following nicotine injections a reduction in Abeta, particularly in the oligomeric form, was found",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 22,
      "key": "12902f79b0590253ce5490acddceb65852966a3928d8fafa8827dc4e9fef0648b89e48523fd4dff0eb7a2fa5cd2da6bb6e7657cf899da87f735d85e7f02c929c"
    },
    {
      "line": 609,
      "relation": "increases",
      "evidence": "The long-term nicotine treatment caused faster tau aggregation in CA1 pyramidal neurons",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true,
          "CA1 Region, Hippocampal": true
        }
      },
      "source": 9,
      "target": 16,
      "key": "03fb49ba672e5fe4d37a83934695a569d23bc189d9d3797c98c80845b1dd130167da90cef7685945e25270ec1b320e70c7b33f777312e0bd12c2a01e41fcab3d"
    },
    {
      "line": 614,
      "relation": "increases",
      "evidence": "The possible mechanism by which nicotine enhances the aggregation of tau is through the activation of p38-MAP kinase",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 16,
      "key": "a487e813a59e7cfa4d33ec839bad2188500ba461e3598a63ee0ff01da6e624e4960b6888f36d77e4daf6375a39508570709fc792ac308d363f5d9a5d91e21fa7"
    },
    {
      "line": 615,
      "relation": "increases",
      "evidence": "The possible mechanism by which nicotine enhances the aggregation of tau is through the activation of p38-MAP kinase",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 49,
      "key": "10c4e42d004c8e3b4c3348ed3f20a93b03589d006b675cea95dcfb13ba55e9416c042c4594329e652107863d6dccf6fb16b56ef33305489faf69a837ba1356f2"
    },
    {
      "line": 626,
      "relation": "decreases",
      "evidence": "Even though nicotine showed a positive effect reducing plaque load (Hellstrom-Lindahl et al., 2004; Inestrosa et al., 2013; Nordberg et al., 2002), its use in AD treatment should be limited due to its toxic effect on tau pathology",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 120,
      "key": "3ffb5329a2b3ea3c3d69dd41eb7fafe99b1a58b219330c42d13e34172b1f317f7034b3c3d98c5f4d2421c482069aff166bdb43ffe18e2678097f38f5ae20a3a1"
    },
    {
      "line": 632,
      "relation": "increases",
      "evidence": "Nicotine treatment improved the memory deficit, highlighted with the Morris water maze task. Surprisingly, this study showed a dose dependent increase of alpha7 nAChR, a result that is in contrast with the literature (Oddo et al., 2005)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 58,
      "key": "438ff33f2cbfc20c0d64c0e943593d7c7aedad42c32af62bd42902a268d6126b44b1d3a95b16cab7aabeeb3e31f4b6322399d7ef628717806a5dac1205cd83e8"
    },
    {
      "line": 654,
      "relation": "increases",
      "evidence": "Wild-type mice treated with nicotine or with SSR180711, another partial agonist of alpha7 (Biton et al., 2006), showed increased LTP, while the transgenic AD model APPSwe/PS1DE9 showed no effect on LTP following SSR180711 treatment",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 46,
      "key": "0765c713bb9ecd8557549abba02ca1a62512baebe2dbb737ffa5f7621a83e18889fc1a1f1ab795bdcc45743c3a65e379f7ccf546e070a1a93cd601d7031f0636"
    },
    {
      "relation": "hasComponent",
      "source": 78,
      "target": 9,
      "key": "e2552457cc78db0b4e97f6dd4085a1cf09be4795673bc8b1f050df3a6307c4d456894e164591ea9df9ff54ddb9cb39002f7316b66a810322a62d63095a132867"
    },
    {
      "relation": "hasComponent",
      "source": 78,
      "target": 88,
      "key": "3325f77c1e1011808c60ff80639a25f7651d517db6e44a51af38db935a5e69bac57d6803f5583755bfb3a31efda3c58cca3886fe5fbd79b903cad1525d004c5a"
    },
    {
      "line": 153,
      "relation": "increases",
      "evidence": "In addition to nAChRs and mAChRs, the enzyme choline acetyltransferase (ChAT), involved in ACh production, is also affected in AD. The activity of this ChAT enzyme, and consequently the synthesis of ACh, is decreased in AD brains",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 94,
      "target": 6,
      "key": "f240d567b312bf1df93cd3974ec35b45b834bd7df3e4464fd9290e8418c5286c51d359a7238687374bf2c39f836173381893024609291073edf58f3c0ae18b6f"
    },
    {
      "line": 163,
      "relation": "increases",
      "evidence": "In addition, several authors observed a reduction in the activity of acetylcholinesterase (AChE), the enzyme that metabolises ACh after its release in the synaptic cleft (Auld et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Davies and Maloney, 1976; Perry et al., 1978)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 91,
      "target": 38,
      "key": "2fb7c7a758fc8f2b65bb76528f13e7bbd5d56abb3f498da5498eb527d425862965b9bf9940a5ecc96415acd70f3f737df454895017d9e47a7016d1279d0d0420"
    },
    {
      "relation": "hasMember",
      "source": 26,
      "target": 89,
      "key": "2275b398d742ffcfad2d3e63d39dbeb45a06332e3e4345402f687a3802f85d67577b29a8f31c089e64c6d325f4d3491c4cd626972591075cd1df339c691e6821"
    },
    {
      "relation": "hasMember",
      "source": 26,
      "target": 90,
      "key": "f3698614359e92fddd96aa9a1d469403e02b473eadbc61ccba3793d73af3314f6c78db415cacbb104f3eccc609f15fbcdb4170b99e78bcd541a235f395c7c2f5"
    },
    {
      "relation": "hasMember",
      "source": 26,
      "target": 28,
      "key": "7108d6269a525d08c84ee4aef6f2cdf2f11ab0eadb7c316f6a4f630757667ff202922683ee39095f95da4c223aad45460000c3a1f9524691e35c3bdff1b9df85"
    },
    {
      "relation": "hasMember",
      "source": 26,
      "target": 30,
      "key": "305e5f28beaf0de8a9c7563c568895b7cde65ee19f7ddf642b2e31ad1809affc515660718b2b07ffdc88cc5c2c34abb2f2ad61ac135461c13575b8c8aefff1a9"
    },
    {
      "line": 240,
      "relation": "negativeCorrelation",
      "evidence": "The subtype alpha4beta2 is characterized by lower calcium ion permeability and a slow desensitization rate compared to the homopentameric alpha7 nAChR (Quick and Lester, 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 40,
      "target": 17,
      "key": "d16c9a786f647d69af3935cf205f7cfd20e51c910d316d89d37a29191c1a8ff5d5359172143fbe6d03fb616754973461bc284f5202a660522252051361a3b5ad"
    },
    {
      "line": 241,
      "relation": "positiveCorrelation",
      "evidence": "The subtype alpha4beta2 is characterized by lower calcium ion permeability and a slow desensitization rate compared to the homopentameric alpha7 nAChR (Quick and Lester, 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 40,
      "target": 32,
      "key": "e6c27107fc3cef3875625362bfba4ade1a11583635f8dcd0a82ad0f6a852807719a0a1f7ad3a28da6cf69edebfc01c394a7f3fbed43f14ac98576057ab389576"
    },
    {
      "relation": "hasComponent",
      "source": 72,
      "target": 3,
      "key": "6ca2c691749f9ea872915cbd8796c4af98480bb987070336174c5c8644a2edf1fb08d40e47072f7a38b842c6d431fbc5972984977be85089889ec31fa70a25f3"
    },
    {
      "relation": "hasComponent",
      "source": 72,
      "target": 101,
      "key": "a531cecbea520b5d662e13969127445e4f392b3137b52412b3f57f2753101e8ce37b8fe1d32c82552a076f4123bba2567447eadb2753a2072acc132ac0fe3164"
    },
    {
      "line": 231,
      "relation": "increases",
      "evidence": "Later it was shown that Abeta is able to activate also beta2*-nAChRs (beta2 subunit-containing nAChRs)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 23,
      "key": "e87db43f054b40c191e711472a92ebdace67961f9fb9f0a8e57d8e29203e4b0da4dcd59d7b61593bb6f5e5a95ad5ecb05bb9a37584bb2d3b0d19053a64f76062"
    },
    {
      "line": 251,
      "relation": "negativeCorrelation",
      "evidence": "This class of receptors seems to be particularly sensitive to Abeta-induced toxicity (Khiroug et al., 2002; Liu et al.,2009, 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 18,
      "key": "a205d3214d99e324850f30dcee36dd3bb554cc0064fcce2854507333c82cade50c03d840b0fb2e872a02e2e35f87ae5b31e6d11a797122ee7c6d15bf05063d51"
    },
    {
      "line": 324,
      "relation": "regulates",
      "evidence": "Modulation of nAChRs by Abeta was also found in ex vivo studies: Pettit and colleagues (2001) used rat hippocampal slices to show that Abeta1-42 incubation is able to reduce postsynaptic currents and open probability of both alpha7 and non-alpha7 nAChRs subtypes, demonstrating an interaction between Abeta and other nAChR subunits",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 89,
      "key": "dd31041a4577cf14f602fe3775c0f7b0da9aaa5f1264a88460883e2004443069b137503df654819b04761a621f58e601329b56075af8c02abc00c6413760ab3d"
    },
    {
      "line": 470,
      "relation": "decreases",
      "evidence": "It was then postulated that Abeta-nAChR interaction has a physiological role in neuronal homeostasis that is disrupted when Abeta concentrations increase in a pathological context, leading to receptor inhibition and possible cellular toxicity (Dineley et al., 2001; Parri et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 89,
      "key": "ea9d5d5bc16d7cffc08818a8dd1918b700e4fbf8921a8ebac0875232bd17fc5075c0d5b7e973f091a51bdfa882833d943d5d23173382249937ecf1b3be3f3c1c"
    },
    {
      "line": 379,
      "relation": "increases",
      "evidence": "A different set of experiments demonstrated that Abeta enhances ACh activation of the alpha4beta2 nAChRs expressed in oocytes, this first activation of the receptor was followed by its inhibition (Pym et al., 2005)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "Cell": {
          "oocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 6,
      "key": "bc48c08c720c28df01d647af999d833c4729d16389ccda397dd0ed4c1ceb2995544ed54e27109bf410c06fb70e1c1172e33ce9e3df801ebb9f103b258a1eb021"
    },
    {
      "line": 386,
      "relation": "increases",
      "evidence": "However, alpha7 nAChR activation was observed in X. laevis oocytes when a range of Abeta concentration spanning from 1 to 100 pM was applied (Dineley et al., 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 32,
      "key": "0fbff833cb4c7391638a3a6adf81d24e1cc83097110c0627990981b063cde4ac8eadd38507bd2d6219cc0b785ecb29cf42a0418100062c7df559bff157b5d07f"
    },
    {
      "line": 461,
      "relation": "decreases",
      "evidence": "In this system enhancement of Akt phosphorylation and activation of ERK pathway was observed following alpha7 agonist treatment, suggesting that Abeta inhibits the neuroprotective effect of alpha7 nAChR activation (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 32,
      "key": "f1a1633dda7450996e65bc23240ba9c105f2f20fe00dadfc120e46652e2a0e1d417c05a91d550fd1885342227db9b3f93d89211bda0ee5952f286b7f2af9677f"
    },
    {
      "line": 448,
      "relation": "increases",
      "evidence": "An in vivo Abeta infusion in mice was able to enhance hippocampal dependent memory, highlighted with memory tasks such as the Morris water maze and contextual fear conditioning, which are both hippocampus dependent behavioural tasks (Puzzo et al.,2008)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 3,
      "target": 58,
      "key": "88120dde48fa08b2316d895d64eb76119f18b16582a48e4839bf857ae78d12cbaafb8481fe886238cb84957c1dbd1ebc74c9389bf19eb3a50c9e2b4f2dc9bebd"
    },
    {
      "line": 471,
      "relation": "decreases",
      "evidence": "It was then postulated that Abeta-nAChR interaction has a physiological role in neuronal homeostasis that is disrupted when Abeta concentrations increase in a pathological context, leading to receptor inhibition and possible cellular toxicity (Dineley et al., 2001; Parri et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 3,
      "target": 47,
      "key": "0e7be9182912a268c83fc8dc93170d8bcb9192a538e1ae875e4578a981755f391b5821c2f869a31c54d26bc2548e532476cc01962e40a5080227a72a3d6994fe"
    },
    {
      "line": 537,
      "relation": "positiveCorrelation",
      "evidence": "With the progression of the disease the amount of Abeta increases, it starts to accumulate, and becomes toxic for the neurons (Hernandez et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 3,
      "target": 117,
      "key": "b267697ab22cde8fd943b0ef36eb25d63f5ad8d51bd3d5ceaabdcf1e937285c89db4f1405eb41ce967eaf99c266351cee71aa0df52500a8dddb89bfe8e475809"
    },
    {
      "line": 605,
      "relation": "decreases",
      "evidence": "The explanation proposed by the authors is that alpha7 nAChR activation through nicotine binding could promote survival pathways and recover the synaptic damage caused by Abeta (Inestrosa et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 3,
      "target": 12,
      "key": "77472d7cf99be9bb7131e7da8d0d2b86a3684765c0df7b92ab215ae16da110add20038fc02641a870cc091dc14db25aa0c069cae07223f8a8675adf78dbd40fc"
    },
    {
      "relation": "hasComponent",
      "source": 73,
      "target": 3,
      "key": "4bf884572e0efa74b8bb34e2ceb093c45a257e0b20167f6bd58d7a9dfe60369f3a7f9983465618574a025b8011ec8c3df4098a095b86391c7529e2548b3bef08"
    },
    {
      "relation": "hasComponent",
      "source": 73,
      "target": 103,
      "key": "f30a689a1d79513cd585606cccbededdfbf39b917d7a9e7c2e6d89b2c300082f60f939a9ac4d0badba17e8387f2b155a18b83dc527d20ab0bdf21a0084d4cc75"
    },
    {
      "line": 203,
      "relation": "increases",
      "evidence": "The alpha7 homomeric receptor demonstrates a wide-spread localization in the brain and is characterized by a high calcium ion permeability and a fast desensitization rate (Dani and Bertrand, 2007; Quick and Lester, 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 40,
      "key": "04ad9d12bc623d3eee07fb0a0e4a6430125dc7068e97ccff3ae394dd3573eb7bc76b6f81c1446bbcaaf143ed2a345e59c1d94aaeca9f002e65783fc0e9ba7f37"
    },
    {
      "line": 241,
      "relation": "positiveCorrelation",
      "evidence": "The subtype alpha4beta2 is characterized by lower calcium ion permeability and a slow desensitization rate compared to the homopentameric alpha7 nAChR (Quick and Lester, 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 40,
      "key": "113c7c60951316600af3af6049650353f1f2ab87572d2179a7072890ce31cec4a955216342ec893d8c3bd63ca69fe6ff1dde324341bc8e07acbd8b24a96b84c5"
    },
    {
      "line": 213,
      "relation": "regulates",
      "evidence": "alpha7 nAChR on presynaptic terminals mediate release of others neurotransmitters (Wonnacott et al., 2006), while a postsynaptic or somatic localization elicits important changes in intracellular Ca++ concentration, that can activate second messenger pathways mediating cellular processes such as neuronal survival and gene expression (Berg and Conroy, 2002; Messi et al., 1997; Morley and Happe, 2000)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 32,
      "target": 8,
      "key": "5c07aea22e10cce28a1a52bcc551689ad2d32a9d87a3dd7d7686a5c566ff350f8b7db065d0c26b9990647109058d023b8a1f1683d60fd8a130a333633f263262"
    },
    {
      "line": 215,
      "relation": "regulates",
      "evidence": "alpha7 nAChR on presynaptic terminals mediate release of others neurotransmitters (Wonnacott et al., 2006), while a postsynaptic or somatic localization elicits important changes in intracellular Ca++ concentration, that can activate second messenger pathways mediating cellular processes such as neuronal survival and gene expression (Berg and Conroy, 2002; Messi et al., 1997; Morley and Happe, 2000)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cell Body": true
        }
      },
      "source": 32,
      "target": 53,
      "key": "0496c00e684f271e168f3cb05d3b528b09376c0cb93ad56780d436425b385569a006b79e192dfcbf44ef976574882477445486c60b904343ef44707bfb114ff7"
    },
    {
      "line": 216,
      "relation": "regulates",
      "evidence": "alpha7 nAChR on presynaptic terminals mediate release of others neurotransmitters (Wonnacott et al., 2006), while a postsynaptic or somatic localization elicits important changes in intracellular Ca++ concentration, that can activate second messenger pathways mediating cellular processes such as neuronal survival and gene expression (Berg and Conroy, 2002; Messi et al., 1997; Morley and Happe, 2000)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cell Body": true
        }
      },
      "source": 32,
      "target": 47,
      "key": "2f29ec6474b9c46c3893d61ca42843d9ad81b84fde75f5b25716e44d6cd420316d6a52832c95341067635eb034d92bdea38c5b73ee80e7b668ca3d45c3792a5c"
    },
    {
      "line": 217,
      "relation": "regulates",
      "evidence": "alpha7 nAChR on presynaptic terminals mediate release of others neurotransmitters (Wonnacott et al., 2006), while a postsynaptic or somatic localization elicits important changes in intracellular Ca++ concentration, that can activate second messenger pathways mediating cellular processes such as neuronal survival and gene expression (Berg and Conroy, 2002; Messi et al., 1997; Morley and Happe, 2000)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cell Body": true
        }
      },
      "source": 32,
      "target": 43,
      "key": "7feec68aa25a976b585ca418e57d2b9f508213f94b5c768d7b46e6b176b3cb18bdff6358adf70e21ca05717a09167a6e0dc79bafc6b5f00cf1e157d35531e0af"
    },
    {
      "line": 223,
      "relation": "increases",
      "evidence": "Moreover, it was demonstrated that the activation of alpha7 nAChRs is important during development for the maturation of glutamatergic synapses (Lozada et al., 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 11,
      "key": "c0c95354b3ce3206a6624c4a5b00d66ee724d44b3083ec1864ead733bcd66fd6a64a24e90b55500a1373e8ffc01be420d8a90623c04f82c47fedbab5506c98e6"
    },
    {
      "line": 421,
      "relation": "increases",
      "evidence": "In a different study, rat hippocampus and cortex were investigated and the activation of both alpha7 and non-alpha7 receptors was obtained with an enhancement of Ca++ influx into the neuron following the application of picomolar (pM) concentrations of Abeta1-42",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 32,
      "target": 4,
      "key": "a1552da9e7c8fe56c57890ea780a4985e66e426fdd91684a6cde50184ff17fc6e988687f2b3b5ec101673160c5b6c461da413ed631a8a159866d2772049f2245"
    },
    {
      "line": 558,
      "relation": "regulates",
      "evidence": "The incubation with S 24795 was able to normalize Ca++ influx mediated by both alpha7 nAChR and NMDAR (Wang et al., 2009, 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 32,
      "target": 4,
      "key": "5b001d368050da7b1e7bfb2413b88b54b2ce0d8e88a2334f3ec52ede01496b3703158a79429565eb6f353adfa167266a12baa64251576ddd82740564e5536180"
    },
    {
      "line": 440,
      "relation": "increases",
      "evidence": "This enhancement of synaptic plasticity and the activation of intracellular pathways are mediated by the activation of alpha7 nAChRs (Dineley et al., 2001; Parri et al., 2011; Plant et al., 2003; Puzzo et al., 2008)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 50,
      "key": "9d2b476a2931c99deb14f439bfcd45f2b17d6f983963ca141ffd33096eb0aa0685d0813d3b06c2326193352ae2a93e9150039f5c318644004d6dc24a58d6a23c"
    },
    {
      "line": 668,
      "relation": "increases",
      "evidence": "It was proposed that the positive action of PREGS is mediated by alpha7 nAChR",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 50,
      "key": "891f5cde86234ba6ea267f8cac9fb759631cc364927c90016f5dab210b83727b55ecc19b04a99d53b433095330687f5cade587026808e3fc040df1fff5379283"
    },
    {
      "line": 441,
      "relation": "increases",
      "evidence": "This enhancement of synaptic plasticity and the activation of intracellular pathways are mediated by the activation of alpha7 nAChRs (Dineley et al., 2001; Parri et al., 2011; Plant et al., 2003; Puzzo et al., 2008)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 44,
      "key": "81ff3fe164758a293df10402c7310b790694bc611346805cf39b7f0b922754c46fa8501ca44276b3e5ff7b48179bae185c8bebc439f2a081aa29f3ee7921d242"
    },
    {
      "line": 459,
      "relation": "increases",
      "evidence": "In this system enhancement of Akt phosphorylation and activation of ERK pathway was observed following alpha7 agonist treatment, suggesting that Abeta inhibits the neuroprotective effect of alpha7 nAChR activation (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 87,
      "key": "32c819e96c9bbd71652bf4ec1b699b23486e6a0f7c71f32bcb066c451be26a43dfadf62e97a5b231873fd0a8a1dfeed11606dd8c3d8d3dcf6dc28ff27ed85082"
    },
    {
      "line": 460,
      "relation": "increases",
      "evidence": "In this system enhancement of Akt phosphorylation and activation of ERK pathway was observed following alpha7 agonist treatment, suggesting that Abeta inhibits the neuroprotective effect of alpha7 nAChR activation (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 37,
      "key": "727f3230ba9c5047996a51c10bdb71de973b044255356074b156290c3dd4c7d28f36643542e91f6e1f5564e73aa655ed0dc50149fff7d4963a559530f7d7cbdf"
    },
    {
      "line": 462,
      "relation": "decreases",
      "evidence": "In this system enhancement of Akt phosphorylation and activation of ERK pathway was observed following alpha7 agonist treatment, suggesting that Abeta inhibits the neuroprotective effect of alpha7 nAChR activation (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 32,
      "target": 59,
      "key": "92bbf96b83f0eaa71bfed852236c3c09bb76cd45cadfaf21e4d65e4d5e624877ad0b54f5edfcf2595ae226fde3ab3387b60ebdaacd0050bf0df05981b35b9f48"
    },
    {
      "line": 549,
      "relation": "increases",
      "evidence": "Methyllycaconitine (MLA), an alpha7 nAChR antagonist, showed neuroprotective effect on mouse and rat primary cell culture (Martin et al., 2004)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 59,
      "key": "3fedeb920601e45b41cfb2304bb8e987a50654dee258d2fa4ab5969aec6bf2aa8174206ba5e3832421dc56790b15eef5362119b92bbaba5c5a988cf943347fa0"
    },
    {
      "line": 603,
      "relation": "increases",
      "evidence": "The explanation proposed by the authors is that alpha7 nAChR activation through nicotine binding could promote survival pathways and recover the synaptic damage caused by Abeta (Inestrosa et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 60,
      "key": "2ed1e73e11dcb773e7449df982b9db2c7f42cca96d99526ab78343cb045a31c81291eb5e8b07aaf59b76f576999ffbeca2047d8ab57805a6a184d3a6f8018be3"
    },
    {
      "line": 604,
      "relation": "increases",
      "evidence": "The explanation proposed by the authors is that alpha7 nAChR activation through nicotine binding could promote survival pathways and recover the synaptic damage caused by Abeta (Inestrosa et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 12,
      "key": "5a13ef460a74a534ad468ab2015e9b3f729de768dded3bb2a931f9a77c623624e5a50b1df750d2171bd667874834c398b6f93a218ee457e2688d25e4b0bd5192"
    },
    {
      "line": 666,
      "relation": "increases",
      "evidence": "It was proposed that the positive action of PREGS is mediated by alpha7 nAChR",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 5,
      "key": "97af0271b89465c4ec51b39194ccd6b19c5bf752759d2f9d2f4c69922f9ee4d68466a7d595264cbf2f9f1ce856a43ec2d3a2f1367a5f4a3f225ca56e833d4d06"
    },
    {
      "line": 667,
      "relation": "increases",
      "evidence": "It was proposed that the positive action of PREGS is mediated by alpha7 nAChR",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 57,
      "key": "8bdaac9c6d766700b752462edb2fec7f488b001cafcd495d3b1ae7ecce4de944bbd2aea5e4b000624ad9e9fd9c55e5e44c5d4e89d281dea847bfd862f3e70b91"
    },
    {
      "line": 669,
      "relation": "increases",
      "evidence": "It was proposed that the positive action of PREGS is mediated by alpha7 nAChR",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 55,
      "key": "5eecfa4fa82b78aaf4a57cefe8b04ffdbde4d35c6e815eeba061b1791fe466d687711fb334e86aff2fa1fd59622f4a25e720701682a7265406fdf0a3d804efab"
    },
    {
      "line": 691,
      "relation": "increases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 32,
      "target": 10,
      "key": "0897896a08a28cc83391a058e25589a62ce58fdeda35615436a2b0eac080e19df6f3dcaf9b0f216e3006ab82688df0ef45075bf9d317801b307b8eb1c9198ce8"
    },
    {
      "line": 693,
      "relation": "increases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 58,
      "key": "54ee26217a27b2eef0789ab4c92bd02297baecd21426a797ed434f5cb9354717b59ebfca18f2df96885b1e06437cc0fdaef28039b126150f0362c2f0d2920d49"
    },
    {
      "line": 697,
      "relation": "decreases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true,
          "CA1 Region, Hippocampal": true
        }
      },
      "source": 32,
      "target": 39,
      "key": "30c097363f63dc335173608a59d8ed563acccb33bedab017de6e5363d53dfc421978204866f5a7313d6a152ba440d149f3c49230874d289ce55037ddb9ad9f21"
    },
    {
      "line": 469,
      "relation": "association",
      "evidence": "It was then postulated that Abeta-nAChR interaction has a physiological role in neuronal homeostasis that is disrupted when Abeta concentrations increase in a pathological context, leading to receptor inhibition and possible cellular toxicity (Dineley et al., 2001; Parri et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 47,
      "target": 70,
      "key": "1b46c6c49b8f4d280965566f2ac58b825b145933cb448ac034f92583a8a7e37eb066fec7a666176b841359d922e9adebdbf3a08db04476e86107f75c6c762f4f"
    },
    {
      "relation": "hasComponent",
      "source": 81,
      "target": 98,
      "key": "4e1a057c746665f5f9a1ef5f7cb55cca4a846183d1fdf51fb946be04dc68922d6707cba1f308a3f8bed826faa7a7ac091cfdcaa785ad11e3f1103f87ff75228a"
    },
    {
      "relation": "hasComponent",
      "source": 81,
      "target": 103,
      "key": "aae43c9e88eb8c7018e403f5882f818acbbde1d8580bc5ef238d29f1995e5adf24d59c3651561e1cfd059750d237b43e16aed54e029890a7d56185667945ae96"
    },
    {
      "line": 236,
      "relation": "increases",
      "evidence": "This subunit commonly forms heteropentameric receptors in combination with the alpha4 subunit",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 81,
      "target": 17,
      "key": "d758b912613d5f2b6494c3437ab4062aaecd9ed6a1e54b55a1aa2a504670ae52ced552592f588d745f4ff54b1bd3f261807d1807ddccd00e43dfd637e2f6904b"
    },
    {
      "line": 240,
      "relation": "negativeCorrelation",
      "evidence": "The subtype alpha4beta2 is characterized by lower calcium ion permeability and a slow desensitization rate compared to the homopentameric alpha7 nAChR (Quick and Lester, 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 17,
      "target": 40,
      "key": "411e763283d2b99e04fc7aa5a3fc6192f583f71d873b029148577c78a545b2f496b806d53e568b7e839589dc1bdf8ebe774867f02b4e8829b051efb75fd2971c"
    },
    {
      "line": 414,
      "relation": "decreases",
      "evidence": "Arora et al. (2013) investigated, in a cellular system, the effect of prolonged Abeta exposure on nAChR function. The rodent neuroblastoma cell line NG108-15 was transfected with alpha4beta2 nAChRs and treated for three days with 100 nM Abeta. The following acute stimulation with Abeta and nicotine led to receptor activation that caused a perturbation of intracellular calcium homeostasis followed by mitochondrial dysfunction and increased oxidative stress (Arora et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 41,
      "key": "600774b8356e599c51eadd276ee8cac906bc6d9c6de556616c99c4fd50ce97babc5102ab73cb7665998ca4d2cf7e117d7a8df162074cbc37082a21e1af13a22e"
    },
    {
      "line": 415,
      "relation": "increases",
      "evidence": "Arora et al. (2013) investigated, in a cellular system, the effect of prolonged Abeta exposure on nAChR function. The rodent neuroblastoma cell line NG108-15 was transfected with alpha4beta2 nAChRs and treated for three days with 100 nM Abeta. The following acute stimulation with Abeta and nicotine led to receptor activation that caused a perturbation of intracellular calcium homeostasis followed by mitochondrial dysfunction and increased oxidative stress (Arora et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 116,
      "key": "147b700a6db5f488b93baeba102e9fd80ac839d0332593fc428086530bf436ba49c5b2433174d19cc1ca1793a3ee346a888be20df256a563cae01c1746db0b3a"
    },
    {
      "line": 416,
      "relation": "increases",
      "evidence": "Arora et al. (2013) investigated, in a cellular system, the effect of prolonged Abeta exposure on nAChR function. The rodent neuroblastoma cell line NG108-15 was transfected with alpha4beta2 nAChRs and treated for three days with 100 nM Abeta. The following acute stimulation with Abeta and nicotine led to receptor activation that caused a perturbation of intracellular calcium homeostasis followed by mitochondrial dysfunction and increased oxidative stress (Arora et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 52,
      "key": "f55e373f41b7520ee498ef68833712337fcd32d4daa4e8cd1825776a83c28854d5e0b1353194a941b87a67a9162df0f3924d1a62c0f058952191c040c19fb26c"
    },
    {
      "relation": "hasComponent",
      "source": 82,
      "target": 101,
      "key": "410e30ec06b3e4ded5f7651cdcaf206193adc0d78c81af84e4b3876c42b0da6e7c0667a36acab792f7237234fcd6289a1fc79c687fde39d7c75d019783a301f3"
    },
    {
      "relation": "hasComponent",
      "source": 82,
      "target": 103,
      "key": "6905df47be8cb95af9956ccebc7de7b73550beec535dd6ef693b36c61981059d613f9162b71c03c6f42de806efc32c8e4a8e2271c8b00cc0be99cf99cf3345bd"
    },
    {
      "line": 246,
      "relation": "increases",
      "evidence": "In addition to the alpha4beta2 subtype, it was demonstrated that the alpha7 subunit is able to coassemble with the beta2 subunit to form a heteropentameric receptor",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 82,
      "target": 18,
      "key": "b38869b31f3336e78e04a4637727ec96cf3ef3ab59de4425c386c652a2e930ce5bfec98019afdafea6d487e1c8f3fbdf37be502e330616048a92b06acaa3f7f5"
    },
    {
      "line": 255,
      "relation": "increases",
      "evidence": "Under these experimental conditions, alpha7 and beta2 are able to co-assemble into a functional receptor that localizes at the cell surface",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "cell surface"
          }
        }
      },
      "source": 82,
      "target": 18,
      "key": "a5a183a58009ee52749dc7819248cf784a90b9860f07547d0c88f1249814a017dd46387b60fbc44b7883db5337261b4334592defad87f5dac675e31a21b08e1c"
    },
    {
      "line": 251,
      "relation": "negativeCorrelation",
      "evidence": "This class of receptors seems to be particularly sensitive to Abeta-induced toxicity (Khiroug et al., 2002; Liu et al.,2009, 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 18,
      "target": 3,
      "key": "f8fdb625fb9ac7a7d4d4ce18c1df1253506d2c03fe05cc54066adb1f142157f0e409074a4c2b3188efc08c1acb0149bc8719ed559a275f8c15bdaf3f7dba8e70"
    },
    {
      "line": 260,
      "relation": "regulates",
      "evidence": "The importance of beta2 in maintaining brain homeostasis during normal ageing was highlighted in the KO mouse for this subunit",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "source": 112,
      "target": 62,
      "key": "8468d588aeffc60317290a52e9335efb4df73abebbd8c8a439cae7ccaf0843e6bc3672b2cf6e666ca79a29eb53d97a682c9cdef6e1388d11e984e7e83f25f6a8"
    },
    {
      "line": 267,
      "relation": "increases",
      "evidence": "Aged beta2 null mutant mice have a thinner cortex compared to agematched wild-type controls (Zoli et al., 1999). This work should be pursued further as it indicates a âneurotrophicâ action of beta2 receptor activation by endogenous ACh (Zanardi et al., 2007)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 112,
      "target": 25,
      "key": "62e5c840e452878ef30f3c375e108ff5601cf6e6299e46391f24309daf86b45ec7580985fa23dc02c59ce4d5f759cc18600d6606f7a9674bc62b8a0d02cbec7d"
    },
    {
      "line": 274,
      "relation": "increases",
      "evidence": "Null mutant beta2 mice were also tested to determine the role of this subunit in cognition. Guillem et al. (2011) showed that these mice exhibit an attention deficit which was restored by re-expression of this subunit with a lentiviral vector in the PFC",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 112,
      "target": 122,
      "key": "9c6a40383bd60075ab34e3ad37eb022d857517378a0a4d076f0d03aedce29c8a0478025860e0f7f80e5c42569d01e7a2bd4a1f3abd9e0fddc3f75f0f01407c7a"
    },
    {
      "line": 275,
      "relation": "increases",
      "evidence": "Null mutant beta2 mice were also tested to determine the role of this subunit in cognition. Guillem et al. (2011) showed that these mice exhibit an attention deficit which was restored by re-expression of this subunit with a lentiviral vector in the PFC",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 112,
      "target": 57,
      "key": "1b1bce426bcdfeda5b8f08735a22a630021f1fd2a1be7db7a71466693e3347739b4156a26fddcef6b03a035eb8fc60e8193003e0ecb8965f71b4e4de003f699e"
    },
    {
      "relation": "hasComponent",
      "source": 69,
      "target": 3,
      "key": "ae6d72ceb66bb384362a3129701b81d3a983e0533d560c701c19d14b05e2b4f6631d0d132600a80cc95cbb5a266e939107a815a7d2bc10ce80d91962e0d4472b"
    },
    {
      "relation": "hasComponent",
      "source": 69,
      "target": 32,
      "key": "fc040eb5b5994fdc376edde38c3d76ba57f574e0ebdef14a8298e8f326969425b4e344c70195f12d5c1e5095f6502ec10f253747ef6dc3c8ab9cb9b29dc454a2"
    },
    {
      "line": 531,
      "relation": "decreases",
      "evidence": "The mechanism proposed is that the AÃ-alpha7 nAChR interaction could activate neuroprotective downstream pathways (Parri et al., 2011), and that at the same time the interaction engages Abeta preventing its aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 69,
      "target": 59,
      "key": "f6a7d8df90e7bde44f8aa8701af0169cf52baf7b38f04494b8bd145085cf2f2e2e3613095adbf6deab2d8fc9efa5d7efaf6c09dea778c9d1ff5eae0708b26743"
    },
    {
      "line": 532,
      "relation": "decreases",
      "evidence": "The mechanism proposed is that the AÃ-alpha7 nAChR interaction could activate neuroprotective downstream pathways (Parri et al., 2011), and that at the same time the interaction engages Abeta preventing its aggregation",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 69,
      "target": 21,
      "key": "2f2432a3ba93318988a11d4bad44af4fce332e74fd165bf29fd5d06d736878281a6fa77480cbc05d4804c3aa54f8040c252f6112e25eafce2569fdfa18b1bc04"
    },
    {
      "relation": "hasComponent",
      "source": 66,
      "target": 2,
      "key": "1b84261bd7deee675dd680094aa1becb19f7501c64ae8c5aabef42796dbb78fd3994eb79d86551ee264afeecc9a14b7d68929cb29951d93b5191ea2027f83b95"
    },
    {
      "relation": "hasComponent",
      "source": 66,
      "target": 101,
      "key": "8fdf320ec4cc0aec22d9a738f0ef73234c990d528ca67438b31936b325c5730ca98f47f1cd2a7880ddf93f16593c8d85dce1aa9a8ee505dabef91ecc67d77c89"
    },
    {
      "line": 283,
      "relation": "association",
      "evidence": "They showed that alpha7 subunits co-localize with Abeta1-42 in senile plaques of brain slices obtained from patients that suffered from sporadic AD",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 66,
      "target": 120,
      "key": "478177f9baf8541923a6eb54ab2c4287dfe4fd9a8edc36260a94b293284dfe61f240a720727425377a657a155d62cc91b07a675fd411e04eea0e336ecf302c1b"
    },
    {
      "line": 325,
      "relation": "decreases",
      "evidence": "Modulation of nAChRs by Abeta was also found in ex vivo studies: Pettit and colleagues (2001) used rat hippocampal slices to show that Abeta1-42 incubation is able to reduce postsynaptic currents and open probability of both alpha7 and non-alpha7 nAChRs subtypes, demonstrating an interaction between Abeta and other nAChR subunits",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 2,
      "target": 61,
      "key": "9876fe437196a5b3476c62e4a68e2821c5ab7954b9d86152b4c4958bd10446ba6aa744943fa8bc006463959aa34471e59299906e625220af20335ba87c954dcd"
    },
    {
      "line": 352,
      "relation": "decreases",
      "evidence": "They demonstrated that Abeta1-42 drives a reversible inhibition of nAChR-mediated currents in hippocampal GABAergic neurons recorded from rat slices. In these experimental conditions the most effective Abeta1-42 concentration was 500 nM, but inhibition was found also at the lower concentration of 100 nM",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "GABAergic neuron": true
        }
      },
      "source": 2,
      "target": 61,
      "key": "4716a3cd0ba268dc5eb0f6c2950c0b64fa6d862a0043841229b0550432439ae76ecd56ce65e217096d41e81ae98e22376c989f9d5f8b7bcc0b55cd2f2ed991ad"
    },
    {
      "line": 350,
      "relation": "decreases",
      "evidence": "They demonstrated that Abeta1-42 drives a reversible inhibition of nAChR-mediated currents in hippocampal GABAergic neurons recorded from rat slices. In these experimental conditions the most effective Abeta1-42 concentration was 500 nM, but inhibition was found also at the lower concentration of 100 nM",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "GABAergic neuron": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 89,
      "key": "c620618b9b44b1343d6e51dbf298b2317bf375fb58867b1b88a3e0f799610db49276dfc196865c06c71eab58d86de8b8515836061add5dd6594e099a2064028a"
    },
    {
      "line": 362,
      "relation": "decreases",
      "evidence": "With the use of selective antagonists it was possible to determine that inhibition operates on both alpha7 and non-alpha7 receptors (Pettit et al., 2001)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 89,
      "key": "f3c55c7ce304575af651e751382d716b808b032ae9f8fd0f3c83b0798f1868f17aad14ac39529c44ff85cb7b87c7eb21ec980baed84f04394f2a62969314aa16"
    },
    {
      "line": 361,
      "relation": "decreases",
      "evidence": "With the use of selective antagonists it was possible to determine that inhibition operates on both alpha7 and non-alpha7 receptors (Pettit et al., 2001)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 32,
      "key": "b4e492bda7518c7134ca2e5d797d05cbc17a560c161cba8dbfd020aea662b01ca4b75553af240259df4d2951e2d5123e49b256fd6522974db34721de0db0b6f6"
    },
    {
      "line": 392,
      "relation": "decreases",
      "evidence": "The incubation of cultured rat hippocampal neurons with Abeta1-42 resulted in inhibition of alpha7 nAChRs, more precisely of both somato-dendritic and presynaptic populations of receptors",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 32,
      "key": "d6d447e537f312828352c52047842d8fe04c8585819a63415fc433335a508ac5446b2a88d80501e693d140f584a51dcb891e602f0fe70da38a497ccea5cfbc4f"
    },
    {
      "line": 399,
      "relation": "decreases",
      "evidence": "Further studies showed an inhibitory effect of Abeta1-42 on human alpha4beta2 nAChRs transfected in the cell line (SHEP1) (Wu et al., 2004)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 17,
      "key": "f2c82bed72fd258072c2cf4814617cc58475bd76ffd924b0909a52edbde4604c79ae60c0abbde69c46da5cab60a1b9f542b7ec6801e9e871c04e9a1cd276b3b7"
    },
    {
      "line": 435,
      "relation": "increases",
      "evidence": "Subsequent to incubation with pM concentrations of Abeta1-42 monomers and oligomers, an increase of hippocampal LTP was observed",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 2,
      "target": 46,
      "key": "4cd18c7e7eaca4b15433377e119bce99f14875185d021831b41fd74a17fcfae1240589e42a2643dc66543e87a113329f0012cadcef71535a33e417f45c2449c1"
    },
    {
      "line": 295,
      "relation": "increases",
      "evidence": "Experiments performed with fragments of Abeta helped identify the sequence responsible for the interaction with alpha7, which corresponds to the amino acid residues 12-28 of the Abeta sequence (Wang et al., 2000b)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 93,
      "target": 80,
      "key": "5cdd0737439cac0f2b78d84de56d92727fbc32b400275f4f6a711ea41e1f163334803ad130b942dab1175f1a6f0579bcb9fbb010cca4c7bbcdea4873c0f5cc8f"
    },
    {
      "relation": "hasVariant",
      "source": 92,
      "target": 93,
      "key": "2cfb493988f08cefed98c1f412b3b66ba81bde58e07c928981362d516dd3d0c32ec7705388b9e7a7d17a430455ccd823191ab6a2afcb1aa49f7959d9b1c54feb"
    },
    {
      "relation": "hasComponent",
      "source": 80,
      "target": 93,
      "key": "24ad62e18d62b39ee5f43272e50b62c9702a8c48c35c7abadbf1bd7559cb81c7af1ca7d533c04424c4fdf5a4da7335f16c284bf5ac45e7e3c3d8fe80d1720e98"
    },
    {
      "relation": "hasComponent",
      "source": 80,
      "target": 101,
      "key": "67f3ca0bfdabfe58edaa62ed057d30b0ccfe92850e5f1ca463dee8338f0f84dc1f3ebf931b4065409feddddfa386179959ca8ac88fa3f8f9e5313a65e7634855"
    },
    {
      "line": 301,
      "relation": "decreases",
      "evidence": "Subsequently, competition studies performed by incubating alpha7 nAChRs with Abeta and alpha-Bungarotoxin showed that the application of alpha-Bungarotoxin is able to decrease the amount of Abeta bound to alpha7 nAChRs, suggesting that both molecules compete for the same ligand binding domain (Wang et al., 2000b)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 33,
      "target": 69,
      "key": "84c03f669dc6b3be2dee18a2ceb4460b961b6d484a99e2798c0649305791804abf9e9e2a4aa1aa78994123b2c51c5674aec0962d28f08d8b8474d997949e65ba"
    },
    {
      "relation": "hasComponent",
      "source": 63,
      "target": 1,
      "key": "b6128fc2dc80ae6f4691d3145827bf63b46e980d9015c21284a44adb152f28f7ffe11c499ac2f8bc72baeb6efe41972ac3f19570c2f00549be37a89dedfdde69"
    },
    {
      "relation": "hasComponent",
      "source": 63,
      "target": 32,
      "key": "a99608d58ac7236e1dd1e4023013c06ac9d5627bac6b924edaff9b608adab07ce9471d4d592c1734249a1223b5eab6a5b962d26b43598d74e858f442a5f25a0e"
    },
    {
      "line": 371,
      "relation": "decreases",
      "evidence": "Experiments performed on X. laevis oocytes transiently transfected with alpha7 or alpha4beta2 cDNA showed a concentration dependent effect of Abeta on receptor inhibition. In this case the peptide used was Abeta1-40 and the concentrations adopted were between 0.1 and 10 mM, with increased Abeta concentration resulting in a bigger inhibition of the receptor (Tozaki et al., 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "Cell": {
          "oocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 17,
      "key": "444aa35a605d90376634352354400298b51f91749202c71aff40166b1da18bf7cc9061db91570f5cfadcd28e6dc339223f918e42ba4a186e10adcc809023aa94"
    },
    {
      "line": 372,
      "relation": "decreases",
      "evidence": "Experiments performed on X. laevis oocytes transiently transfected with alpha7 or alpha4beta2 cDNA showed a concentration dependent effect of Abeta on receptor inhibition. In this case the peptide used was Abeta1-40 and the concentrations adopted were between 0.1 and 10 mM, with increased Abeta concentration resulting in a bigger inhibition of the receptor (Tozaki et al., 2002)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "Cell": {
          "oocyte": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 32,
      "key": "b0bd5277ec29796aea2aa6e6fca6f80edcd07af89d6537c1e06902fe7dd6cea69529a405a9874725e842de59b5ae7e3bdf1a67559fa4938f4cf5c4eff786f8ba"
    },
    {
      "relation": "hasComponent",
      "source": 65,
      "target": 2,
      "key": "7b07f901812d3c65353a67cc18ecc5aaeeed7b8fdeab5e541b52fc532a7cbb285acc3060aea45f42a94f7341b8bcbe0d2d6b5740fbb43588101c34d03fe76976"
    },
    {
      "relation": "hasComponent",
      "source": 65,
      "target": 32,
      "key": "a9192c920db5695eeb25cf0f3c37ba12811a985b14e898c8b91d8242c3056a66f8c579d5ae57072e91128e290093b14544437bdd58f6fcfc1de1f1293f0a32c2"
    },
    {
      "relation": "hasComponent",
      "source": 74,
      "target": 3,
      "key": "0c70222b3e1d3e297d5584dab4cbf9f34bac60881e6ca407ee6dc7914fef087386a30c5c22ff6e2f63021ab410e84b3c32feb55a01b995b25cb53a925861c80c"
    },
    {
      "relation": "hasComponent",
      "source": 74,
      "target": 111,
      "key": "f18cde7bc9748aaf8599c618e7573dd6df50776f913f50c3f18d1bc7f7676f2a2f5cb9399bf2db810fe328d9efa74a7dea56c7f29de5b2d6ac0772648f595d37"
    },
    {
      "line": 484,
      "relation": "decreases",
      "evidence": "This AD model displays spatial memory deficit at 13-16 months of age, while APP-alpha7KO mice did not exhibit any memory deficit, suggesting that the absence of the alpha7 subunit of the nicotinic receptor protects against the behavioural deficit caused by expression of the mutated forms of APP in this AD model",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 121,
      "key": "d5ec66f55a7464f877c09ee6afade009bc4990c8fe0e28ba70ce5d559a3df9a68fc63d52a610ca7e91398bb7bb078e45b134347dd72509dbfcf860c027de198c"
    },
    {
      "line": 489,
      "relation": "decreases",
      "evidence": "In the APP-alpha7KO line the lack of alpha7 was sufficient to preserve synaptic terminals and dendrites, rescuing levels of synaptophysin and MAP2 to reach that of aged-matched WT controls",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 114,
      "key": "3e5bd9fc71eaf5f6446db9a838a570598b5406d739a64c1095f7757448d9cf891dff1fac1921cdfff9d47623800da70c5450689e95f4e372c1a288e93ad36b16"
    },
    {
      "line": 490,
      "relation": "decreases",
      "evidence": "In the APP-alpha7KO line the lack of alpha7 was sufficient to preserve synaptic terminals and dendrites, rescuing levels of synaptophysin and MAP2 to reach that of aged-matched WT controls",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 113,
      "key": "bdb939b65ba45923294bda3310d89ce3d98bcb224785092f93f38f7e6b7342ed93b8c3d0b637ba7e365c40e4e1b7b29d87c26a70986781e0b871c04ec4031650"
    },
    {
      "line": 525,
      "relation": "increases",
      "evidence": "Signs of neuropathology were found in APP-alpha7KO illustrated by loss of MAP2 immunoreactivity in the hippocampus",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 111,
      "target": 113,
      "key": "f67d8f60c004a9c429ef02e5e5304a8f7cacc2bdc8ae6889c3a1f7a0676c357745591287133c69910432e6fc8c7edb9a46190d8be33597c295a10676d8ea6b5e"
    },
    {
      "line": 502,
      "relation": "increases",
      "evidence": "The authors postulated that the absence of alpha7 could prevent Abeta intracellular accumulation ameliorating the cognitive neuropathology and its phenotypic association (Dziewczapolski et al., 2009)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 3,
      "key": "93349634a246f4b739fa085097e178f5b6f54aa8c9e38b007f92a855e72049973ce35b1be8e751a90215b9550967bc26208cb6b1cf508672e96cc644768e61f5"
    },
    {
      "line": 515,
      "relation": "decreases",
      "evidence": "In the hippocampus, it was shown that APP-alpha7KO mice had high levels of Abeta, although significantly less than APP mice, an effect which is not due to modification of the APP expression level,equivalent in the two lines",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 111,
      "target": 3,
      "key": "1a40878f01872a3a05911984f7c06a20d5eba05709f806d6ea4dcbfa478c6e2c7b00e364c7269f2b4a18682cf8c5c6ff69c450b8c6a982fab22c66136c93e782"
    },
    {
      "line": 503,
      "relation": "increases",
      "evidence": "The authors postulated that the absence of alpha7 could prevent Abeta intracellular accumulation ameliorating the cognitive neuropathology and its phenotypic association (Dziewczapolski et al., 2009)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 57,
      "key": "32cfa9434d1664c2aa2c11597911b7dda6d4218eff9f56f99f226d9811c015654c5e3527bb2f001e5d0b820eb359c33c73536f68e3321e7a5371b891b833f3b8"
    },
    {
      "line": 509,
      "relation": "decreases",
      "evidence": "The contextual fear conditioning and the novel object recognition tasks both showed that the cognitive deficits worsen when alpha7 is absent",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 118,
      "key": "c8e6c9f7f729cd485343d566ea8b6bc7b7ab249de11f22c0fefbd09a8f94a06bce6434905d6850d1291aa1a822a399a6618460ada2657543dcd5869610dd3b01"
    },
    {
      "line": 520,
      "relation": "increases",
      "evidence": "As a consequence of the lower Abeta concentration, the plaque load was clearly reduced in APP-alpha7KO mice",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 111,
      "target": 120,
      "key": "f20bb27de202ffc3f6fe323128b6cdf2bd8125d0ad8e483be6a3c28e01e1333b23d35b253d92a50f93041542981f3ec73241a225ab34c443d62a9ee1668cd3ee"
    },
    {
      "relation": "hasComponent",
      "source": 64,
      "target": 1,
      "key": "a69a0b45133e80a75a9dda9146916d2efc5d366b3691ed35f0a02b07347c36a430bca78a759856f604483b787c1ee8b020f6bfcf851443532f5ac0d2b12d00bb"
    },
    {
      "relation": "hasComponent",
      "source": 64,
      "target": 111,
      "key": "dc1ca4e6e796e304d61a7ca954b8fa0af59a3031ce0e33e9e343ffe6a3cdf7239007f19f7ac5d5e022f51d51469657029bfe5e71f81b82e19b86914cae708bc6"
    },
    {
      "relation": "hasComponent",
      "source": 67,
      "target": 2,
      "key": "94aa63645d06d13e4b2b75508bdba97d119c1cd04e69c7e26f9eac986d881f9b16bccf5f7cf3dccf41e077f9566d2ed8e62f092d928da21d9304c3fc6ca44a55"
    },
    {
      "relation": "hasComponent",
      "source": 67,
      "target": 111,
      "key": "92d41ef1d0dae4e2f3d2041381414784f2f84ab708c623fd72015fdbd4994fd32d5de87b7741f37b463b58c7cc498427e146b492534e4eb39febf96d4d95834a"
    },
    {
      "relation": "hasComponent",
      "source": 70,
      "target": 3,
      "key": "68dd625258b7c81697cca091711e6bdd60ff28ca3125985493ee268f966e2fdb655041bfccf51fccf913dc8492716bebd505ffbc2e2c5cffc3cedba322af4be2"
    },
    {
      "relation": "hasComponent",
      "source": 70,
      "target": 89,
      "key": "53ab4490d744175a660727fa9dbc7ad22b7012d89728395f9fc9bd901faec5e2f37f0e0d7e6143c483b90d3b2ce6bef7bebc0cb89baabad68d890671fbb614ab"
    },
    {
      "line": 425,
      "relation": "increases",
      "evidence": "However, it is clear that nAChR-AÃ interaction initiates intracellular signalling implicating a set of transduction cascades",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 70,
      "target": 44,
      "key": "b215d243a8689888f4d67d64b27d280d9c1e65caf19be22658c2995ddb21d206f38e74c37a338563cbbf58e6c5f3e63469d87c136a0d29b52b9cd8214a0112bb"
    },
    {
      "line": 453,
      "relation": "decreases",
      "evidence": "On the other hand, an opposite effect was shown with Abeta-nAChR interaction being responsible for inhibition of survival pathways",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 70,
      "target": 60,
      "key": "7fa25984bfb50c0eff54ee95d1d6cb11df37b083ea19e4a8f8042b7aee47bac6379e4129cd12bf7645d30c9bbf16d498659370f4623a47441853ee04918b2a9c"
    },
    {
      "line": 469,
      "relation": "association",
      "evidence": "It was then postulated that Abeta-nAChR interaction has a physiological role in neuronal homeostasis that is disrupted when Abeta concentrations increase in a pathological context, leading to receptor inhibition and possible cellular toxicity (Dineley et al., 2001; Parri et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 70,
      "target": 47,
      "key": "a74c3ea4e441839fce7c465b12fc50b87998afc0421ed9bb2039fcbfdb0fca2423c83c8ff8d660cffea2ae8125bb4d846ba418533d2a5fccb52f15a5d7c0a48a"
    },
    {
      "relation": "hasComponent",
      "source": 75,
      "target": 3,
      "key": "67f90111b19209e948d93dca1a204a1d11602cc0432f55d4347353ae9b4d1e00a5523ba027483c590e1ac3b719c7c63307f0a02e696482c6925b04e60459ada2"
    },
    {
      "relation": "hasComponent",
      "source": 75,
      "target": 115,
      "key": "efc256c67ea03a78f7a0f3a3d5da5f62daa753aed66aa7eee7d566f129a01ed7a96761803f4894da3ec049c479f539bb50eecc51231a03dcd9808abe5e17b340"
    },
    {
      "relation": "hasComponent",
      "source": 68,
      "target": 3,
      "key": "3ac496a6b308310de8e9b85afbe42c3caa5fdd963f454c9519995c334e191bd4ba58c945d2f03796c02d6b88b87c1dc1f232b6c63062d6a110195a4a63ecb4ff"
    },
    {
      "relation": "hasComponent",
      "source": 68,
      "target": 23,
      "key": "9dcdc9781f2299a6c1dfddd06f1af3a104fe1808641cb52debae3221304f12da86e080a27b629a838375333892662729bf10122782c5bc3a4151ec3a55de4b97"
    },
    {
      "line": 337,
      "relation": "increases",
      "evidence": "In both hippocampal interneurons and oocytes they observed a block of beta2*-nAChRs, that could be prevented by the application of a positive allosteric modulator (PAM) specific for beta2 subunit containing receptors, desformylflustrabromine (dFBr) (Pandya and Yakel, 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 35,
      "target": 23,
      "key": "2ee97ddb0cd27a924caa1b3cd03f3c5f5e83478fa0368411140e8c1adae8d4d01a6e747e95cafe49cd5433249cf5d408ce16624cca0b1ce41bcb0bbb086727a2"
    },
    {
      "line": 403,
      "relation": "increases",
      "evidence": "The oligomeric form of Abeta1-40 was able to activate alpha7 nAChR expressed in SH-SY5Y cell line (Lilja et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 32,
      "key": "56e8773c1c3ae749ca9f79c70abb3e17b3ee16f70db6eca361ea9ae4fadcdb2ff1550fe57cfe70979ce1c3d9dc57538dca42c560fd4bc250b3d9d9c80779e1ed"
    },
    {
      "relation": "hasComponent",
      "source": 84,
      "target": 3,
      "key": "62c9d39c97ccdd2459350ef0bd9066ca60d8a0a2afdfd6b2044815126a1532151b89051ee746fada169074a4afbda0d840a3da41f1718518a2a1d6ec2e065f8f"
    },
    {
      "relation": "hasComponent",
      "source": 84,
      "target": 9,
      "key": "ab7e4bf2a16a8e9fa2a619d33a1735bcd43c0cad087293c82957c12c3a44a5b7becc525947a1bccb2d7451ba5f777fb350da2c10793c886ff96b5bef9bd1c19c"
    },
    {
      "line": 413,
      "relation": "increases",
      "evidence": "Arora et al. (2013) investigated, in a cellular system, the effect of prolonged Abeta exposure on nAChR function. The rodent neuroblastoma cell line NG108-15 was transfected with alpha4beta2 nAChRs and treated for three days with 100 nM Abeta. The following acute stimulation with Abeta and nicotine led to receptor activation that caused a perturbation of intracellular calcium homeostasis followed by mitochondrial dysfunction and increased oxidative stress (Arora et al., 2013)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 84,
      "target": 17,
      "key": "43b81798eb23fc6976db141b2c7e38b89f3a540bb4ba1fecce08de425a618e12554f60524b3ca42bf3eff5a488ca19bbd31da62d14e6c6e123bf85f796e7faed"
    },
    {
      "line": 429,
      "relation": "decreases",
      "evidence": "Akt phosphorylation mediates the downstream activation of an antiapoptotic pathway, which is also activated by nicotine treatment (Kihara et al., 2001)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 87,
      "target": 39,
      "key": "749ad9210cae98df365c6cdf64a610e0a6837bfbae2d02ea181defddac6ddfffe33545850b79e8ee590e311a3d8f7fb6ec9a5dc2c1c34825a2a198711db42d3a"
    },
    {
      "relation": "hasVariant",
      "source": 86,
      "target": 87,
      "key": "e116efc1e42b1489df61c436ffaafcd0372249b6e2dd4b3fe8b8586cae5efcc671048f5065d7e0a9164d380e4e7e449feee77aef4181eeb18af8d249b730ced3"
    },
    {
      "line": 639,
      "relation": "decreases",
      "evidence": "In a mouse model of AD, cotinine treatment decreased the plaque load and was able to activate the Akt pathway, that was shown to be neuroprotective (Echeverria et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 86,
      "target": 59,
      "key": "83ddf08350125475afeb96368828c66ebb7bc0b06ea60b31322d2a0a2b6d90f3f12c6ec0ef9ffd47309a3e99ed8a39a72936a260a44e684c8f5818a7a84a059a"
    },
    {
      "line": 434,
      "relation": "increases",
      "evidence": "Subsequent to incubation with pM concentrations of Abeta1-42 monomers and oligomers, an increase of hippocampal LTP was observed",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 20,
      "target": 46,
      "key": "e8098a8c1917b084d1dba0502d6de044c55e5546c44005d27071f9ffc520a161629883c52a8d2d9b77bbc4a39b5ee11124ea393ee6dcc3411bd8a689c834597c"
    },
    {
      "line": 483,
      "relation": "decreases",
      "evidence": "This AD model displays spatial memory deficit at 13-16 months of age, while APP-alpha7KO mice did not exhibit any memory deficit, suggesting that the absence of the alpha7 subunit of the nicotinic receptor protects against the behavioural deficit caused by expression of the mutated forms of APP in this AD model",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 110,
      "target": 121,
      "key": "4e9e7bf6d771c7e455f82de360964cc52d7056e9631044578a7817d78fe667893f5612b05f52c7e132b402e8a35131052fee167f8ea30cbf158b013e21e0a787"
    },
    {
      "relation": "hasVariant",
      "source": 108,
      "target": 110,
      "key": "ebf3977cd6eecb9b2aa59493ec200fad1bf27f0e264c1edacb2d7257ff41a6f1da2f49f5b96842990f701f43717cd3146a7c2c93848cea9071e89267112baede"
    },
    {
      "relation": "hasVariant",
      "source": 108,
      "target": 109,
      "key": "33f9f3edd4049a2ec86bf6be7b2776c2273ebaf85a502c51ae15e6df9d29231dbdad233bce3230f82e808a15bc97cae0ffa00fb6df6e0da710bce19db8c560c2"
    },
    {
      "line": 538,
      "relation": "positiveCorrelation",
      "evidence": "With the progression of the disease the amount of Abeta increases, it starts to accumulate, and becomes toxic for the neurons (Hernandez et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 21,
      "target": 117,
      "key": "0c7fad872cfbe113386c3bd149cb09d6a682ada496ca6583aad387763c4df3a65c08dcba90f05bb1066e98fc9cd2d01bd4c1d59fa9474506b2b69c60d44da1ca"
    },
    {
      "line": 542,
      "relation": "increases",
      "evidence": "Cotinine is a nicotine metabolite known for its positive effects on memory and attention and lower toxicity compared to nicotine (Hatsukami et al., 1997)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 122,
      "key": "ca33fb698765cf4450f1615faa9f9edbbda6b73d41bdd023e81673b12b9eb1d52bd77f08e011eee0f0cc530d90084574b8fa2d254b8911c93788b361b952f809"
    },
    {
      "line": 543,
      "relation": "increases",
      "evidence": "Cotinine is a nicotine metabolite known for its positive effects on memory and attention and lower toxicity compared to nicotine (Hatsukami et al., 1997)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 58,
      "key": "c0f16e59d63a964828269c9c77ddf75aa7ed5aac53c0666b69715a2d4381ce11020d293701f3fa1ee9df99f398fc366338b46ee5d7d9d6575e8aa99f78517235"
    },
    {
      "line": 637,
      "relation": "decreases",
      "evidence": "In a mouse model of AD, cotinine treatment decreased the plaque load and was able to activate the Akt pathway, that was shown to be neuroprotective (Echeverria et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 120,
      "key": "bbd90cad61733e178ce6f322be861ba5df61c36efb7a4b34573e1ebf7e44d9fa604100f8b2ceabf1c9da6b38ea20ea99e645c8e56bfb202b33906e994546b08e"
    },
    {
      "line": 638,
      "relation": "increases",
      "evidence": "In a mouse model of AD, cotinine treatment decreased the plaque load and was able to activate the Akt pathway, that was shown to be neuroprotective (Echeverria et al., 2011)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 86,
      "key": "24d74d7a977f94d83c266ac949ef5473ccb244d749de4c4126f892b68a2c5490eb75816daed8c9aea558edd1d40f3f3f47250a1052ed78bc4604527b3958e6c3"
    },
    {
      "line": 642,
      "relation": "increases",
      "evidence": "Cotinine is an alpha7 nAChR PAM (positive allosteric modulator)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 32,
      "key": "1f40322d4be20d78d3932ad8e56f169bc480d23cd2a056537e9926d9c177da4cf3435d0071044ce48a3f83c89f72de0638760a2c307242fc97f0bca2afd41c3a"
    },
    {
      "line": 547,
      "relation": "decreases",
      "evidence": "Methyllycaconitine (MLA), an alpha7 nAChR antagonist, showed neuroprotective effect on mouse and rat primary cell culture (Martin et al., 2004)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 32,
      "key": "a410f0a3378c0af4de1f12cd806489f17415ef587eebe012e20153ea2345b6cd87e9e00262235b84b9fbcd793d4f2d831b65de1814f0d580313593b66fdd3c00"
    },
    {
      "line": 548,
      "relation": "decreases",
      "evidence": "Methyllycaconitine (MLA), an alpha7 nAChR antagonist, showed neuroprotective effect on mouse and rat primary cell culture (Martin et al., 2004)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 7,
      "target": 59,
      "key": "232c23b7c72a934e1b00701fb40b3559d0f95407a33c3d501330b3613beba40a539f9d8505bbc4af043aa53a7fb5872e60e3b12af8203f68c5c12eab65fee094"
    },
    {
      "line": 554,
      "relation": "decreases",
      "evidence": "Another molecule investigated was 2-[2-(4- bromophenyl)-2-oxoethyl]-1-methyl pyridinium (S 24795), a partial alpha7 nAChR agonist. When this molecule was applied to synaptosomal preparations from rat frontal cortex and post mortem human AD samples it was able to dissociate Abeta in a concentration dependent manner",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 15,
      "target": 3,
      "key": "05555d85102da28aaee468291fb48e1f21ca63175cd9fa56101ff0c721af521dc5be59869d1d79c17809ac884ace336c13af965d6f5d16b633221292fb6ec756"
    },
    {
      "line": 560,
      "relation": "increases",
      "evidence": "The incubation with S 24795 was able to normalize Ca++ influx mediated by both alpha7 nAChR and NMDAR (Wang et al., 2009, 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 15,
      "target": 4,
      "key": "e95915e338417ca60663ce34df37328a71d99b56c88a58944af5c4c04920f8c2064529fec91e2c7b8e91cf87e564c83495dc8bddbec15b315ebbab3f02de394b"
    },
    {
      "line": 559,
      "relation": "regulates",
      "evidence": "The incubation with S 24795 was able to normalize Ca++ influx mediated by both alpha7 nAChR and NMDAR (Wang et al., 2009, 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 29,
      "target": 4,
      "key": "c1b46b00dd828dd21b1255597dc86f2c4448c4e5b65bb64ff0ae335e80b58001cbd897f2b53f44418aca55e7ef77b726b97bb690e153e32690c267ba6be6b993"
    },
    {
      "line": 616,
      "relation": "increases",
      "evidence": "The possible mechanism by which nicotine enhances the aggregation of tau is through the activation of p38-MAP kinase",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 49,
      "target": 16,
      "key": "ed93ffc2f94f63c1acf166fc5f5de0c7eb72c517ea96cc9a2567f405a40d6f48ffab028a07aac67b93f5c6ee2e746708a323dc4f57866af98bdc2f74e76b1ec5"
    },
    {
      "line": 647,
      "relation": "increases",
      "evidence": "Whilst the spatial memory deficit was restored by 4OH-GTS-21 treatment, this molecule had no effect on neuronal density (Ren et al., 2007)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 13,
      "target": 121,
      "key": "459781cc6240c443d26ca2cdd3d77abc6411f4044df2c89dbaf97840521dd188d5e2f702f22d718004c1aa9c1dc2a2aa9a21dd1d6eb75b6d5aa0344b1c7ae25c"
    },
    {
      "line": 648,
      "relation": "causesNoChange",
      "evidence": "Whilst the spatial memory deficit was restored by 4OH-GTS-21 treatment, this molecule had no effect on neuronal density (Ren et al., 2007)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 13,
      "target": 47,
      "key": "52cda23f781a6ed6d47816d3c723fe9335812b93a07b015a876b64fc8a4442473bccda0f42115fa6d09a37ead5afe1ccd039b052732739371dba2e4cb6571a83"
    },
    {
      "line": 655,
      "relation": "increases",
      "evidence": "Wild-type mice treated with nicotine or with SSR180711, another partial agonist of alpha7 (Biton et al., 2006), showed increased LTP, while the transgenic AD model APPSwe/PS1DE9 showed no effect on LTP following SSR180711 treatment",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 36,
      "target": 46,
      "key": "4b1e000bda7f8ab2a39ba26a6c8d50f247e4cc676b5b639cb3d37de8596e01a2cb1f243fd32be73c5f7932880e571854130a39c7fd2734c8605c6142d9a6248e"
    },
    {
      "line": 661,
      "relation": "increases",
      "evidence": "Pregnenolone sulfate (PREGS) is an endogenous steroid known to ameliorate cognitive performance in animals. PREGS is a modulator of synaptic plasticity, acting on the activation of glutamatergic transmission (Smith et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 57,
      "key": "867407fd99e2cc3812063b91456c2a07479ed3506a1837655e9a8a65ccc4d9ae50b12ada8b4f52d2e46f34c2d6fa5a3cc4ee567a41032797032b54bc17d8399b"
    },
    {
      "line": 662,
      "relation": "increases",
      "evidence": "Pregnenolone sulfate (PREGS) is an endogenous steroid known to ameliorate cognitive performance in animals. PREGS is a modulator of synaptic plasticity, acting on the activation of glutamatergic transmission (Smith et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 50,
      "key": "20f4cf935cd34968e0b280a908fff86cda843f7f6050321ef9a0ffa14532e19e3a3362232d6f5408316ff85acb78c1cd97a4fa5d06f5644b2c0534f7e7651f7b"
    },
    {
      "line": 663,
      "relation": "increases",
      "evidence": "Pregnenolone sulfate (PREGS) is an endogenous steroid known to ameliorate cognitive performance in animals. PREGS is a modulator of synaptic plasticity, acting on the activation of glutamatergic transmission (Smith et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 55,
      "key": "790386c896e7324be7c611a18b33a7c08ffa55f7ffb0df7ebaa8ba0db88a4bcef299249c07b4da897a9464362649cfc162421835428ffd0e80d22e95d5f77ab6"
    },
    {
      "line": 673,
      "relation": "increases",
      "evidence": "The treatment improved spatial memory and reduced apoptosis in CA1 pyramidal cells",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 121,
      "key": "fab9e7ea158b6c1b01d508693f84a48ce8d6d0b9e74015e419b2e19a26c4500e6f1f90530922ff5e80c858a07ba107288f9fb918e41e1115e4276fb1e53c6238"
    },
    {
      "line": 675,
      "relation": "decreases",
      "evidence": "The treatment improved spatial memory and reduced apoptosis in CA1 pyramidal cells",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true,
          "CA1 Region, Hippocampal": true
        }
      },
      "source": 5,
      "target": 39,
      "key": "9bc84e66286b715a30a4a3ccd0bc4b1a2bd20456a0078991f8a488cae7d4042ef0b1ba91ea84b6fb8143864323001032bf943d262c23d693b39358248d403f4a"
    },
    {
      "line": 681,
      "relation": "regulates",
      "evidence": "Simvastatin (SV) is a statin commonly used in the clinic to control cholesterol levels and it was shown to improve cognitive function in AD patients (Simons et al., 2002; Sparks et al., 2006)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 10,
      "target": 42,
      "key": "caa9c6f6fe50d6b9c8d069fdd5d9a162c0f59f3afe1be9295ea25f0d42c1ac0b3f3901db57b2975e284deffac49eab069a7841c00069132526cdc021669222fa"
    },
    {
      "line": 682,
      "relation": "increases",
      "evidence": "Simvastatin (SV) is a statin commonly used in the clinic to control cholesterol levels and it was shown to improve cognitive function in AD patients (Simons et al., 2002; Sparks et al., 2006)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 10,
      "target": 57,
      "key": "8ee486e5ce775756e1f5f530d5b20d05757a261cf2389a0f4614f3563251d6c34150248617e466e03e52ae19652b89af7d432001c982d02078bc1088456f000e"
    },
    {
      "line": 696,
      "relation": "decreases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Pyramidal Cells": true,
          "CA1 Region, Hippocampal": true
        }
      },
      "source": 10,
      "target": 39,
      "key": "6b44b2f41a9ad2d8e63c02c337e3383a15a24ce5b6c702818635f98c2cab299cef341e42b021667995d32eeab0cb69332b7abc33f97dac438f63c384c9ae930a"
    },
    {
      "relation": "hasComponent",
      "source": 85,
      "target": 10,
      "key": "57c02b02b61fd3b51368b2f787f58bf67cf78317175c9631fc75be61e57e6a4bbad8d69fba268550a403fbfd8360eb598f7a053a8083c769725d7f863def26ef"
    },
    {
      "relation": "hasComponent",
      "source": 85,
      "target": 109,
      "key": "26d08914431ff4f008813fe8c58cb6e9fd1565c5987a0b7dc13e7ef96301c6bffd15bc5b6c244658325ab9ffd52000d7e047a3f91f9314965afc4cf3079e501c"
    },
    {
      "line": 692,
      "relation": "increases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 85,
      "target": 58,
      "key": "4f9712b52124e4578080963b7eb7bb7cd85671e62f863c3dea856083878357ff5d54ed1c1bb735d604b7218bccda6629ef240ea236c535fcdc790907385eea47"
    },
    {
      "line": 694,
      "relation": "decreases",
      "evidence": "In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse model obtained with injections of the peptide AÃ25-35. Administration for 11 days of SV improved memory performance in the Morris water maze task and promoted survival of CA1 pyramidal cells. This effect was proposed to be promoted by alpha7 nAChRs, since it is blocked by MLA administration (Zhi et al., 2014)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 34,
      "target": 32,
      "key": "921416edf0051517976df6667c07bbbb74780b65f35be69127d9a9c2e3212fe8cb4a26a1c7b3b69bdfaeb7d6c14015b9594a47644ce0751dd28ee0138c9f8385"
    },
    {
      "relation": "hasComponent",
      "source": 71,
      "target": 3,
      "key": "6fa75d543b83bdf9207f5dec37563eff2e1fa110ab1d72cc9fdbf19ff4c63f70743b95d5eb9ac747b38181f13655dfb172fae8fe2777b9165a06fda708995f66"
    },
    {
      "relation": "hasComponent",
      "source": 71,
      "target": 89,
      "key": "a83693c8cbc823f8d4542acfb9dd95f573ad685b8363bd9160e0d8a17a9497388dd4d9e8038373167145819ee81ca17d9c8683ad779557b108a5484358cde39d"
    },
    {
      "relation": "hasComponent",
      "source": 71,
      "target": 106,
      "key": "abafeaa557edd033461050f27452ca3e16062942e8a18c21ed87a999b3fd3fa1bb3c25c8149764fcc1e0a9d3144363ba70b36066f082aea7964a04cdb532b128"
    },
    {
      "line": 707,
      "relation": "increases",
      "evidence": "The intracellular signalling initiated by the binding of Abeta to nAChR at the cell surface requires the recruitment of Filamin A (FLNA), a scaffold protein that is known to crosslink actin, and in addition could also have a function in certain intracellular pathways (Stossel et al., 2001)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 71,
      "target": 44,
      "key": "4ac7dfa2764df488f397834c7f629fd0bd936d30af2219a2b257e5560c679b1e617580b884c8e32ff76c61aa649eecdefd301273c54118dbdffe02dbdb26a498"
    },
    {
      "relation": "hasComponent",
      "source": 83,
      "target": 101,
      "key": "72a9b25b2d1117976ab3ede6a9d5f74d304673b3e9f15c1e805172430910c83f79ba68c6bf0c5c14b7d9c7d5a3057c0f21f98ba2b3f24560edf0b0dbee98259d"
    },
    {
      "relation": "hasComponent",
      "source": 83,
      "target": 106,
      "key": "f14f03dcf48a2ff7def7547ced0de88921c8bd71ea739ff45782636ddce2b0836a024ac1389d7094de0f8aaf162d25cb10ce2b8d8fcdacc9b0e82fc43a9e1d1e"
    },
    {
      "line": 711,
      "relation": "positiveCorrelation",
      "evidence": "Wang et al. showed that the association between FLNA and the alpha7 subunit is elevated in AD samples compared to age matched controls",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 83,
      "target": 117,
      "key": "6f64954abf05c287ac19835dfb9a95fd0c533e204e32c5c6f69a0ee0565b624aa2bfad758c9f5aeb679f70a989fd6773412125d5b9bded8e6cbf840ed02aa1bf"
    },
    {
      "line": 717,
      "relation": "decreases",
      "evidence": "A novel molecule called PTI-125 was used to interfere with the interaction of FLNA and alpha7. The treatment with PTI-125 prevents FLNA binding to alpha7 and as consequence reduces the affinity of Abeta for nAChRs, attenuating the toxic effect of Abeta (Wang et al., 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 14,
      "target": 83,
      "key": "1e09b05a6ded10091a8645e1817e39dad1a5815659938e1b6386360732d662edf7c69fdc301a32b936af89115678a0cc43d7e57fe9d8a17ca9408e0dc4a23131"
    },
    {
      "line": 718,
      "relation": "decreases",
      "evidence": "A novel molecule called PTI-125 was used to interfere with the interaction of FLNA and alpha7. The treatment with PTI-125 prevents FLNA binding to alpha7 and as consequence reduces the affinity of Abeta for nAChRs, attenuating the toxic effect of Abeta (Wang et al., 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "source": 14,
      "target": 70,
      "key": "c5ff97baec34a15941b230d31a1bdbb2ef831380e83c9d8b795472a7533984e330179cb84ff3c43964b913e6b5cebd9435864483b81cf6c58edf90cb9619f3ce"
    },
    {
      "line": 719,
      "relation": "increases",
      "evidence": "A novel molecule called PTI-125 was used to interfere with the interaction of FLNA and alpha7. The treatment with PTI-125 prevents FLNA binding to alpha7 and as consequence reduces the affinity of Abeta for nAChRs, attenuating the toxic effect of Abeta (Wang et al., 2012)",
      "citation": {
        "type": "PubMed",
        "reference": "25514383"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 3,
      "key": "3f7ca52509ce04490c744fb4a70dd6a9bb4f37f5d1735879fd049a9dc921436c3ea5c1409bad3cbf9d172d26b6bbc3bc68968b5b49888af38500345085bc18d0"
    }
  ]
}